{"id":284618,"date":"2024-12-18T01:36:00","date_gmt":"2024-12-17T17:36:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=284618"},"modified":"2024-12-18T01:36:00","modified_gmt":"2024-12-17T17:36:00","slug":"menarini-group-%e5%85%ac%e4%bd%88%e8%a9%95%e4%bc%b0-obicetrapib-%e5%8f%8a%e5%9b%ba%e5%ae%9a%e5%8a%91%e9%87%8f%e8%a4%87%e6%96%b9%e8%a3%bd%e5%8a%91-obicetrapib-%e8%88%87-ezetimibe-10-mg-%e7%9a%84","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=284618","title":{"rendered":"Menarini Group \u516c\u4f48\u8a55\u4f30 Obicetrapib \u53ca\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291 Obicetrapib \u8207 Ezetimibe 10 mg \u7684\u95dc\u9375\u6027\u7b2c\u4e09\u671f BROADWAY \u53ca TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>\u2014\u2014 \u5169\u9805\u95dc\u9375\u6027<\/i>\u00a0<i>\u7814\u7a76\u5747\u9054\u5230\u00a0\u4e3b\u8981\u7d42\u9ede\uff0c\u5728\u6700\u5927\u8010\u53d7\u5291\u91cf\u7684\u964d\u8102\u6cbb\u7642\u57fa\u790e\u4e0a\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (LDL-C) \u7684 LS \u5e73\u5747\u503c\u986f\u8457\u964d\u4f4e (p&lt;0.0001)\u3002<\/i><\/li>\n<li><i>\u2014\u2014 \u5728 BROADWAY \u7814\u7a76\uff08Obicetrapib \u55ae\u85e5\u6cbb\u7642\uff09 \u4e2d\uff0c\u7d04 50% \u7684<\/i>\u00a0<i>\u60a3\u8005<\/i> <i>\u9054\u5230 LDL-C \u76ee\u6a19\u503c\u4f4e\u65bc 55 mg\/dL\uff1b \u800c<\/i> <i>\u00a0\u5728 TANDEM \u7814\u7a76\uff08Obicetrapib \u8207 Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff09\u4e2d\uff0c\u5247\u6709\u8d85\u904e 70% \u7684\u60a3\u8005\u9054\u5230\u76f8\u540c\u76ee\u6a19\u503c\u3002 <\/i><\/li>\n<li><i>\u2014\u2014 \u5728 BROADWAY \u7814\u7a76\u4e2d\uff0c\u4e00\u5e74\u6642\u89c0\u5bdf\u5230 Obicetrapib \u7684\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6<\/i>\u00a0<i>\u6e1b\u5c11<\/i> <i>\u4e86 21%\uff0c\u986f\u793a\u51fa Obicetrapib \u7684\u512a\u52e2<\/i><\/li>\n<li><i>\u2014\u2014 \u65bc\u5169\u9805\u7814\u7a76\u4e2d\uff0cObicetrapib \u55ae\u85e5\u7642\u6cd5\u53ca\u8207<\/i>\u00a0<i>Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5747\u986f\u793a\u51fa\u826f\u597d\u8010\u53d7\u6027 \u00a0<\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">\u610f\u5927\u5229\u4f5b\u7f85\u502b\u85a9<\/span><span class=\"legendSpanClass\">2024\u5e7412\u670817\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; Menarini Group\u4eca\u65e5\u516c\u4f48\u7531NewAmsterdam Pharma Company N.V. \uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS \u6216\u300cNewAmsterdam\u300d\u6216\u300c\u8a72\u516c\u53f8\u300d\uff09\u8d0a\u52a9\u7684\u7b2c\u4e09\u671fBROADWAY (NCT05142722) \u53caTANDEM (NCT06005597) \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da\u3002NewAmsterdam\u662f\u4e00\u5bb6\u5f8c\u671f\u81e8\u5e8a\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u70ba\u60a3\u6709\u9ad8\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\uff08\u300cLDL-C\u300d\uff09\u4e14\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\uff08\u300cCVD\u300d\uff09\u98a8\u96aa\uff0c\u800c\u73fe\u6709\u7642\u6cd5\u672a\u80fd\u5145\u5206\u6709\u6548\u6216\u826f\u597d\u8010\u53d7\u7684\u60a3\u8005\uff0c\u7814\u767c\u53e3\u670d\u975e\u4ed6\u6c40\u985e\u85e5\u7269\u3002<\/p>\n<p>\u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57 (NCT05142722) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg\u00a0Obicetrapib \u5728\u60a3\u6709\u7570\u5408\u5b50\u5bb6\u65cf\u6027\u9ad8\u81bd\u56fa\u9187\u8840\u75c7 (\u300cHeFH\u300d) \u53ca\/\u6216\u5df2\u78ba\u8a3a\u52d5\u8108\u7ca5\u6a23\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u75be\u75c5 (\u300cASCVD\u300d)\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002<\/p>\n<p>\u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57 (NCT06005597) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u548c 10 mg Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5728\u60a3\u6709 HeFH \u53ca\/\u6216\u5df2\u78ba\u8a3a ASCVD \u6216\u6709\u591a\u91cd ASCVD \u98a8\u96aa\u56e0\u7d20\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u00a0<\/p>\n<p>BROADWAY \u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u662f Obicetrapib 10 mg \u7d44\u76f8\u8f03\u65bc\u5b89\u6170\u5291\u7d44\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u7684\u6700\u5c0f\u4e8c\u4e58\u5e73\u5747\u503c\u3002\u4e3b\u8981\u7d42\u9ede\u9054\u5230\u7684\u7d71\u8a08\u610f\u7fa9\u6027\uff0cLDL-C \u964d\u4f4e 33% (p&lt;0.0001)\u3002<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"4\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b><u>LDL-C percentage change at Day 84:<\/u><\/b>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnpr10 prnpl2 prnvab prnsbtb1 prnbrbrs prnbbbs prnbsbls\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Placebo<\/b>\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n=844)<\/b>\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Obicetrapib 10 mg<\/b>\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n=1686)<\/b>\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Difference <\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml10\"><span class=\"prnews_span\">Mean<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-2\u00a0%<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-35\u00a0%<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-33\u00a0%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml10\"><span class=\"prnews_span\">Median<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-4\u00a0%<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-40\u00a0%<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-36\u00a0%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml10\"><span class=\"prnews_span\">LS mean<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+3\u00a0%<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-30\u00a0%<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-33\u00a0%<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>\u89c0\u5bdf\u5230\u7684\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7684\u8b8a\u5316\uff0c\u5305\u62ec\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (\u300cHDL-C\u300d) \u7684\u5347\u9ad8\u4ee5\u53ca\u975e\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\u3001\u8102\u86cb\u767d (a)(\u300cLp(a)\u300d)\u3001\u8f09\u8102\u86cb\u767d B (\u300cApoB\u300d) \u548c\u8f09\u8102\u86cb\u767d A1 (ApoA1) \u7684\u964d\u4f4e\uff0c\u5747\u5448\u6b63\u9762\u8da8\u52e2\uff0c\u4e26\u8207\u5148\u524d\u81e8\u5e8a\u8a66\u9a57\u5831\u544a\u7684\u6578\u64da\u4e00\u81f4\u3002<\/p>\n<p>\u4f5c\u70ba\u5b89\u5168\u6027\u5206\u6790\u7684\u4e00\u90e8\u5206\uff0c\u76e3\u6e2c\u4e86\u7279\u5225\u95dc\u6ce8\u7684\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6 (\u300cAE\u300d)\u3002\u5728\u9019\u4e9b AE \u4e2d\uff0c\u8840\u7cd6\u63a7\u5236\u548c\u814e\u529f\u80fd\u65b9\u9762\uff0cObicetrapib \u7d44\u5747\u512a\u65bc\u5c0d\u7167\u7d44\u3002<\/p>\n<p>\u6b64\u5916\uff0cBROADWAY \u8a66\u9a57\u5c0d MACE \u9032\u884c\u4e86\u88c1\u5b9a\uff0c\u5305\u62ec\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u6027\u4e2d\u98a8\u548c\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u91cd\u5efa\u8853\uff0c\u7d50\u679c\u00a0\u986f\u793a<i> Obicetrapib \u7d44\u7684\u9996\u500b\u56db\u9805 MACE \u4e8b\u4ef6\u767c\u751f\u7387\u964d\u4f4e\u4e86 21%\u3002<\/i><\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"5\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b><u>Major adverse cardiovascular events table:<\/u><\/b>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Placebo<\/b>\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n=844)<\/b>\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Obicetrapib 10 mg<\/b>\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n= 1686)<\/b>\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Hazard Ratio<\/b>\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>95% CI<\/b>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">All-cause mortality \u2013 no. (%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">12 (1.4)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">19 (1.1)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">0.83<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">(0.40-1.71)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Coronary heart death \u2013 no. (%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">5 (0.6)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">8 (0.5)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">0.80<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">(0.26-2.44)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">First 4-point MACE \u2013 no. (%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">44 (5.2)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">70 (4.2)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">0.79<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">(0.54-1.15)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"5\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><i>4-point MACE: C<\/i>\u00a0<i>HD<\/i> <i>\u00a0death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization<\/i> <i>. MACE was not a primary or secondary endpoint of the BROADWAY trial.<\/i> <\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>\u7e3d\u9ad4\u800c\u8a00\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u4ea6\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\uff08\u5305\u62ec\u8840\u58d3\uff09\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002Obicetrapib \u7d44\u4e2d\u6b62\u6cbb\u7642\u7387\u70ba 11.1%\uff0c\u5b89\u6170\u5291\u7684 12.4%\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d)\u3001\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\u4ee5\u53ca\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d) \u7684\u767c\u751f\u7387\u3002<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Placebo <\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n=8<\/b>\u00a0<b>43)<\/b> <\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Obicetrapib 10 mg <\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n=1<\/b>\u00a0<b>,685)<\/b> <\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Any TEAEs \u2013 no. (%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">513 (60.9)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1007 (59.8)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Any trial drug related TEAEs \u2013 no (%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">39 (4.6)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">76 (4.5)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Any TEAEs leading to discontinuation of trial drug \u2013 no. (%<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">43 (5.1)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">68 (4.0)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Any TESAEs \u2013 no. (%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">117 (13.9)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">211 (12.5)<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>TANDEM \u8a66\u9a57\u7684\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u70ba\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5404\u55ae\u85e5\u6cbb\u7642\u7d44\u76f8\u6bd4\uff0c\u4ee5\u53ca Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\u3002\u6b21\u8981\u7d42\u9ede\u5305\u62ec\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7531\u57fa\u7dda\u8d77\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u5305\u62ec Lp(a)\u3001\u975e HDL-c \u548c APO B\u3002<\/p>\n<p>TANDEM \u8a66\u9a57\u9054\u6210\u4e86\u6240\u6709\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u5176\u4e2d\u5305\u62ec\u5728\u7b2c 84 \u5929\u6642\uff0cObicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u9054\u5230 48.6% \u7684 LS \u5e73\u5747\u964d\u5e45 (p &lt; 0.0001)\u3002<\/p>\n<p><b><u>\u7b2c 84 \u5929\u7684 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316<\/u><\/b>\u00a0<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Ezetimibe<\/b>\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n = 101)<\/b>\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Obicetrapib <\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n = 102)<\/b>\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Obicetrapib and <\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Ezetimibe FDC<\/b>\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n = 102)<\/b>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Day 84 \u2013 from placebo<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml10\"><span class=\"prnews_span\">Mean %<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-23.3<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-35.5<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-52.2<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml10\"><span class=\"prnews_span\">Median %<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-22.6<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-37.2<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-54.0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml10\"><span class=\"prnews_span\">LS mean %<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-20.7<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-31.9<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-48.6<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml20\"><span class=\"prnews_span\">Comparison to pbo<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">&#8211;<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">(p&lt;0.0001)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">(p&lt;0.0001)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml20\"><span class=\"prnews_span\">Comparison to eze 10 mg<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">&#8211;<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">&#8211;<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">(p&lt;0.0001)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml20\"><span class=\"prnews_span\">Comparison to obi 10 mg<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">&#8211;<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">&#8211;<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">(p = 0.0007)<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>\u5728\u8a72\u8a66\u9a57\u4e2d\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d) \u53ca\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d)\u3002<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Placebo (n=102)<\/b>\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Ezetimibe <\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n=101)<\/b>\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Obicetrapib <\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n=102)<\/b>\u00a0<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Obicetrapib \/ <\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Ezetimibe FDC <\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n=102)<\/b>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Any study drug-related TEAEs<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">4 (3.9\u00a0%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">3 (3.0\u00a0%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">7 (6.9\u00a0%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">3 (2.9\u00a0%)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Any study drug-related TEAEs leading to discontinuation of study drug<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">2 (2.0\u00a0%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1 (1.0\u00a0%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">6 (5.9\u00a0%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1 (1.0\u00a0%)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Any study drug related TESAEs<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">0 (0.0\u00a0%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">0 (0.0\u00a0%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">0 (0.0\u00a0%)<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">0 (0.0\u00a0%)<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>\u300c\u5fc3\u8840\u7ba1\u75be\u75c5 (CVD) \u662f\u5168\u7403\u4e3b\u8981\u7684\u6b7b\u4ea1\u539f\u56e0\uff0c\u4f30\u8a08\u6bcf\u5e74\u596a\u53bb 1,790 \u842c\u4eba\u7684\u751f\u547d\u3002\u5118\u7ba1\u964d\u8102\u6cbb\u7642\u5df2\u5ee3\u6cdb\u61c9\u7528\uff0c\u4f46\u8207\u5fc3\u8840\u7ba1\u75be\u75c5\u76f8\u95dc\u7684\u6b7b\u4ea1\u4eba\u6578\u6709\u6240\u4e0a\u5347\uff0c\u4e14\u60a3\u8005\u7684 LDL-C \u6c34\u5e73\u4ecd\u7136\u8d85\u51fa\u76ee\u6a19\u503c\uff0c\u8a31\u591a\u60a3\u8005\u672a\u80fd\u9054\u5230\u6307\u5f15\u5efa\u8b70\u7684 LDL-C \u76ee\u6a19\u6c34\u5e73\u3002\u60a3\u8005\u53ca\u5176\u91ab\u751f\u9700\u8981\u5176\u4ed6\u6cbb\u7642\u9078\u64c7\u3002\u6211\u5011\u975e\u5e38\u9ad8\u8208 BROADWAY \u548c TANDEM \u7684\u6578\u64da\uff0c\u4ee5\u53ca\u5148\u524d\u516c\u4f48\u7684 <span class=\"xn-location\">BROOKLYN<\/span> \u6578\u64da\uff0c\u5747\u8b49\u5be6\u4e86 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u80fd\u5920\u986f\u8457\u964d\u4f4e LDL-C\uff0c\u4e26\u5e6b\u52a9\u60a3\u8005\u9054\u5230\u5efa\u8b70\u7684\u76ee\u6a19\u6c34\u5e73\u3002\u9019\u4ee3\u8868\u8457\u6211\u5011\u81f4\u529b\u65bc\u70ba\u6b50\u6d32\u5fc3\u8840\u7ba1\u75be\u75c5\u60a3\u8005\u63d0\u4f9b\u6f5b\u5728\u540c\u985e\u9996\u5275\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u6cbb\u7642\u65b9\u6848\u7684\u91cd\u8981\u91cc\u7a0b\u7891\uff0c\u9019\u4ea6\u662f\u672c\u516c\u53f8\u4e09\u5341\u591a\u5e74\u4f86\u4e00\u76f4\u79c9\u6301\u7684\u4f7f\u547d\u300d\uff0c<i>Menarini Group \u884c\u653f\u7e3d\u88c1 <span class=\"xn-person\">Elcin Barker Ergun<\/span> \u8868\u793a\u3002<\/i><\/p>\n<p><b>\u6a1e\u7d10\u6027\u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08<\/b><\/p>\n<p>\u9019\u9805\u70ba\u671f 52 \u9031\u7684\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u591a\u4e2d\u5fc3\u7814\u7a76\u8a55\u4f30\u4e86 10 mg Obicetrapib \u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u4f5c\u70ba\u6700\u5927\u8010\u53d7\u964d\u8102\u7642\u6cd5\u7684\u8f14\u52a9\u5291\uff0c\u5c08\u9580\u7528\u65bc LDL-C \u7121\u6cd5\u5145\u5206\u63a7\u5236\u7684 ASCVD \u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u8a72\u7814\u7a76\u5728\u5317\u7f8e\uff0c\u6b50\u6d32\uff0c\u4e9e\u6d32\u548c\u6fb3\u6d32\u7b49\u5730\u9032\u884c\u3002\u5171 2,530 \u540d\u60a3\u8005\u88ab\u96a8\u6a5f\u5206\u70ba\u5169\u7d44\uff0c\u6bd4\u4f8b\u70ba2:1\uff0c\u63a5\u53d7\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d 10 mg Obicetrapib \u6216\u5b89\u6170\u5291\u6cbb\u7642\uff0c\u70ba\u671f 52 \u9031\uff0c\u4e26\u4e14\u4e0d\u53d7\u98df\u7269\u5f71\u97ff\u3002\u5118\u7ba1\u8fd1 70% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 Obicetrapib \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 100 mg\/dL\u3002\u5973\u6027\u7d04\u4f54\u7814\u7a76\u5c0d\u8c61\u7684 34%\uff0c\u7814\u7a76\u53c3\u8207\u8005\u57fa\u6e96\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba 65 \u6b72\u3002<\/p>\n<p>\u4e3b\u8981\u7d42\u9ede\u70ba Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u7d93\u586b\u88dc\u6cd5\u5206\u6790\u986f\u793a\u964d\u4f4e\u4e86 33%\u3002\u6b21\u8981\u7d42\u9ede\u4ea6\u5305\u62ec Obicetrapib 10 mg \u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929ApoB\u3001Lp(a)\u3001ApoA1\u3001HDL-C\u3001\u975eHDL-C\u3001\u7e3d\u81bd\u56fa\u9187\u53ca\u7518\u6cb9\u4e09\u916f\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u4ee5\u53ca\u7b2c 180 \u5929\u53ca\u7b2c 365 \u5929\u7684 LDL-C \u6c34\u5e73\uff08\u5206\u5225\u964d\u4f4e 34%\u53ca 24%\uff0cp&lt;0.0001\uff09\u3002\u5176\u4ed6\u7d50\u679c\u6307\u6a19\u5305\u62ec Obicetrapib \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u96a8\u6a5f\u5206\u7d44\u81f3\u9996\u6b21\u78ba\u8a3a\u767c\u751f MACE \u7684\u6642\u9593\u3002\u8a72\u8a66\u9a57\u9084\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\u3002<\/p>\n<p><b>\u6a1e\u7d10\u6027\u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08<\/b><\/p>\n<p>\u9019\u9805\u6a1e\u7d10\u6027\u7b2c\u4e09\u671f\u3001\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u56db\u7d44\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5c0d LDL-C \u6c34\u5e73\u7684\u5f71\u97ff\uff0c\u4e26\u8207 10 mg ezetimibe \u53ca 10 mg Obicetrapib 10 mg \u55ae\u85e5\u6cbb\u7642\u53ca\u5b89\u6170\u5291\u9032\u884c\u6bd4\u8f03\u3002\u8a72\u7814\u7a76\u65bc\u7f8e\u570b\u5404\u5730\u7684\u591a\u500b\u7814\u7a76\u4e2d\u5fc3\u9032\u884c\uff0c\u5171\u6709 407 \u540d\u57fa\u7dda LDL-C \u81f3\u5c11\u70ba70 mg\/dL\uff0c\u4e14\u60a3\u6709 HeFH \u53ca\/\u6216 ASCVD \u6216\u5177 ASCVD \u98a8\u96aa\u7b49\u540c\u60c5\u6cc1\u7684\u60a3\u8005\uff0c\u4ee5 1:1:1:1 \u7684\u6bd4\u4f8b\u96a8\u6a5f\u5206\u914d\u63a5\u53d7 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u300110 mg Obicetrapib\u300110 mg ezetimibe\u6216 \u5b89\u6170\u5291\uff0c\u6cbb\u7642\u671f\u70ba 84 \u5929\u3002\u5118\u7ba1\u7d04 74% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 obicetrapib-ezetimibe \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 97 mg\/dL\u3002\u9664\u8a55\u4f30\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u53ca\u6b21\u8981\u7d42\u9ede\u5916\uff0c\u8a72\u8a66\u9a57\u4ea6\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u3002<\/p>\n<p><b>Obicetrapib\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u8a08\u5283<\/b><\/p>\n<p><b>Obicetrapib \u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u5305\u62ec\u56db\u9805\u7814\u7a76\uff0c\u6d89\u53ca\u8d85\u904e 12,250 \u540d\u60a3\u8005\u3002\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u91dd\u5c0d Obicetrapib \u55ae\u7368\u6cbb\u7642\uff0c\u4e00\u9805\u5247\u8a55\u4f30 obicetrapib \u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u7d44\u5408 (\u300cFDC\u300d)\uff1a<\/b><\/p>\n<ul type=\"disc\">\n<li><span class=\"xn-location\">BROOKLYN<\/span> \u8a66\u9a57 (NCT05425745) \u5c0d\u65bc\u5728 HeFH \u4e0b\u4ecd\u672a\u80fd\u5145\u5206\u63a7\u5236 LDL-C \u7684\u60a3\u8005\uff0c\u8a55\u4f30\u5176\u4f7f\u7528 Obicetrapib \u7684\u6548\u679c\u30022023 \u5e74 4 \u6708\u5b8c\u6210\u8d85\u904e 350 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024\u5e74\u7b2c\u4e09\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002<\/li>\n<li>BROADWAY \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u5c0d\u65bc\u60a3\u6709\u78ba\u5b9a\u7684 ASCVD \u53ca\/\u6216 HeFH \u7684\u6210\u5e74\u60a3\u8005\u7684\u6548\u679c\u3002\u5118\u7ba1\u9019\u4e9b\u60a3\u8005\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46\u5176 LDL-C \u6c34\u5e73\u4ecd\u672a\u80fd\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT05142722)\u30022023 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 2,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74\u7b2c\u56db\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002<\/li>\n<li>TANDEM \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u4f5c\u70ba FDC \u7247\u5291\u7684\u4e00\u90e8\u5206\uff0c\u7528\u65bc\u60a3\u6709 ASCVD \u6216\u591a\u7a2e ASCVD \u98a8\u96aa\u56e0\u7d20\u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u9019\u4e9b\u60a3\u8005\u5118\u7ba1\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46 LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT06005597)\u3002 2024 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 400 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74 11 \u6708\u9304\u5f97\u9802\u7dda\u6578\u64da<\/li>\n<li>PREVAIL \u662f\u4e00\u9805\u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57 (\u300cCVOT\u300d)\uff0c\u65e8\u5728\u8a55\u4f30\u6709 ASCVD \u75c5\u53f2\u7684\u60a3\u8005\uff0c\u5118\u7ba1\u5df2\u63a1\u7528\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0cObicetrapib \u5c0d\u65bc\u90a3\u4e9b LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u60a3\u8005\u7684\u6548\u679c (NCT05202509)\u30022024\u5e744\u6708\u5b8c\u6210\u8d85\u904e9500\u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u3002<\/li>\n<\/ul>\n<p><b>\u95dc\u65bc Obicetrapib <br \/><\/b>Obicetrapib \u662f\u4e00\u7a2e\u65b0\u578b\u7684\u53e3\u670d\u4f4e\u5291\u91cf CETP \u6291\u5236\u5291\uff0c\u65e8\u5728\u514b\u670d\u76ee\u524d\u964d\u4f4eLDL\u6cbb\u7642\u7684\u5c40\u9650\u6027\u3002\u5728\u5404\u9805\u7b2c\u4e8c\u671f\u8a66\u9a57 ROSE2\u3001TULIP\u3001ROSE\uff0c\u4ee5\u53ca\u7b2c\u4e09\u671f\u8a66\u9a57 BROOKLYN\u3001BROADWAY \u548c TANDEM \u4e2d\uff0c\u8a55\u4f30 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u806f\u5408\u6cbb\u7642\u6642\uff0c\u5747\u89c0\u5bdf\u5230\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684 LDL-C \u964d\u4f4e\uff0c\u4e14\u5176\u526f\u4f5c\u7528\u60c5\u6cc1\u8207\u5b89\u6170\u5291\u76f8\u4f3c\u3002<br \/>\u7b2c\u4e09\u671f PREVAIL \u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57\u5728 2022 \u5e74 3 \u6708\u958b\u59cb\uff0c\u65e8\u5728\u8a55\u4f30 Obicetrapib \u6e1b\u5c11\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u7684\u6f5b\u529b\uff0c\u5305\u62ec\u5fc3\u8840\u7ba1\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u4e2d\u98a8\u548c\u975e\u9078\u64c7\u6027\u51a0\u72c0\u52d5\u8108\u518d\u8840\u7ba1\u5316\u30022024 \u5e74 4 \u6708 PREVAIL \u5b8c\u6210\u8d85\u904e 9,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\uff0c\u4e26\u9032\u884c\u96a8\u6a5f\u5206\u7d44\u3002<\/p>\n<p><b>\u95dc\u65bc Menarini Group <br \/><\/b>Menarini \u662f\u4e00\u5bb6\u9818\u5148\u570b\u969b\u88fd\u85e5\u548c\u8a3a\u65b7\u696d\u754c\u7684\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 47 \u5104\u7f8e\u5143\uff0c\u64c1\u6709\u8d85\u904e 17,000 \u540d\u54e1\u5de5\u3002Menarini\u5c08\u6ce8\u65bc\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80ba\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u3001\u708e\u75c7\u548c\u6b62\u75db\u7684\u7522\u54c1\uff0c\u5c08\u6ce8\u65bc\u9ad8\u672a\u6eff\u8db3\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u548c 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u92b7\u5f80\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.menarini.com&amp;esheet=53558844&amp;newsitemid=20230920907427&amp;lan=en-US&amp;anchor=www.menarini.com&amp;index=5&amp;md5=7682feaaefe280a649c9a9d8a9e54a2c\" target=\"_blank\" rel=\"nofollow noopener\">www.menarini.com<\/a>\u3002<\/p>\n<p><b>\u95dc\u65bc NewAmsterdam <br \/><\/b>NewAmsterdam Pharma\uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS\uff09\u662f\u4e00\u9593\u5f8c\u671f\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5176\u4f7f\u547d\u662f\u5728\u73fe\u6709\u5df2\u7372\u6279\u51c6\u7684\u6cbb\u7642\u65b9\u6cd5\u4e0d\u8db3\u6216\u60a3\u8005\u8010\u53d7\u6027\u4e0d\u4f73\u7684\u60c5\u6cc1\u4e0b\uff0c\u6539\u5584\u4ee3\u8b1d\u75be\u75c5\u60a3\u8005\u7684\u8b77\u7406\u3002\u6211\u5011\u81f4\u529b\u65bc\u6eff\u8db3\u5c0d\u5b89\u5168\u3001\u8010\u53d7\u6027\u826f\u597d\u4e14\u4fbf\u6377\u7684\u4f4eLDL\u6cbb\u7642\u7684\u8feb\u5207\u9700\u6c42\u3002NewAmsterdam Pharmaceuticals \u6b63\u9032\u884c\u591a\u9805\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u53e3\u670d\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u7d66\u85e5\u7684 CETP \u6291\u5236\u5291 Obicetrapib \u55ae\u7368\u4f7f\u7528\uff0c\u6216\u8207 ezetimibe \u7d44\u6210\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u4f5c\u70ba\u964d\u4f4e LDL-C \u7684\u6548\u76ca\u3002\u6b64\u7b49\u7642\u6cd5\u64ec\u4f5c\u70ba\u5df2\u63a5\u53d7\u4ed6\u6c40\u985e\u85e5\u7269\u6cbb\u7642\uff0c\u60df LDL-C \u6fc3\u5ea6\u4ecd\u504f\u9ad8\uff0c\u4e14\u5177 CVD \u98a8\u96aa\uff0c\u73fe\u6709\u7642\u6cd5\u7642\u6548\u4e0d\u5f70\u6216\u8010\u53d7\u6027\u4e0d\u826f\u7684\u60a3\u8005\u7684\u8f14\u52a9\u6cbb\u7642\u65b9\u6848\u3002<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2014\u2014 \u5169\u9805\u95dc\u9375\u6027\u00a0\u7814\u7a76\u5747\u9054\u5230\u00a0&#8230;<\/p>\n","protected":false},"author":16,"featured_media":284619,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-284618","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Menarini Group \u516c\u4f48\u8a55\u4f30 Obicetrapib \u53ca\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291 Obicetrapib \u8207 Ezetimibe 10 mg \u7684\u95dc\u9375\u6027\u7b2c\u4e09\u671f BROADWAY \u53ca TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u2014\u2014 \u5169\u9805\u95dc\u9375\u6027\u00a0\u7814\u7a76\u5747\u9054\u5230\u00a0\u4e3b\u8981\u7d42\u9ede\uff0c\u5728\u6700\u5927\u8010\u53d7\u5291\u91cf\u7684\u964d\u8102\u6cbb\u7642\u57fa\u790e\u4e0a\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (LDL-C) \u7684 LS \u5e73\u5747\u503c\u986f\u8457\u964d\u4f4e (p&lt;0.0001)\u3002  \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\uff08Obicetrapib \u55ae\u85e5\u6cbb\u7642\uff09 \u4e2d\uff0c\u7d04 50% \u7684\u00a0\u60a3\u8005 \u9054\u5230 LDL-C \u76ee\u6a19\u503c\u4f4e\u65bc 55 mg\/dL\uff1b \u800c \u00a0\u5728 TANDEM \u7814\u7a76\uff08Obicetrapib \u8207 Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff09\u4e2d\uff0c\u5247\u6709\u8d85\u904e 70% \u7684\u60a3\u8005\u9054\u5230\u76f8\u540c\u76ee\u6a19\u503c\u3002  \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\u4e2d\uff0c\u4e00\u5e74\u6642\u89c0\u5bdf\u5230 Obicetrapib \u7684\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u00a0\u6e1b\u5c11 \u4e86 21%\uff0c\u986f\u793a\u51fa Obicetrapib \u7684\u512a\u52e2  \u2014\u2014 \u65bc\u5169\u9805\u7814\u7a76\u4e2d\uff0cObicetrapib \u55ae\u85e5\u7642\u6cd5\u53ca\u8207\u00a0Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5747\u986f\u793a\u51fa\u826f\u597d\u8010\u53d7\u6027 \u00a0  \u610f\u5927\u5229\u4f5b\u7f85\u502b\u85a92024\u5e7412\u670817\u65e5 \/\u7f8e\u901a\u793e\/ -- Menarini Group\u4eca\u65e5\u516c\u4f48\u7531NewAmsterdam Pharma Company N.V. \uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS \u6216\u300cNewAmsterdam\u300d\u6216\u300c\u8a72\u516c\u53f8\u300d\uff09\u8d0a\u52a9\u7684\u7b2c\u4e09\u671fBROADWAY (NCT05142722) \u53caTANDEM (NCT06005597) \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da\u3002NewAmsterdam\u662f\u4e00\u5bb6\u5f8c\u671f\u81e8\u5e8a\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u70ba\u60a3\u6709\u9ad8\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\uff08\u300cLDL-C\u300d\uff09\u4e14\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\uff08\u300cCVD\u300d\uff09\u98a8\u96aa\uff0c\u800c\u73fe\u6709\u7642\u6cd5\u672a\u80fd\u5145\u5206\u6709\u6548\u6216\u826f\u597d\u8010\u53d7\u7684\u60a3\u8005\uff0c\u7814\u767c\u53e3\u670d\u975e\u4ed6\u6c40\u985e\u85e5\u7269\u3002 \u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57 (NCT05142722) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg\u00a0Obicetrapib \u5728\u60a3\u6709\u7570\u5408\u5b50\u5bb6\u65cf\u6027\u9ad8\u81bd\u56fa\u9187\u8840\u75c7 (\u300cHeFH\u300d) \u53ca\/\u6216\u5df2\u78ba\u8a3a\u52d5\u8108\u7ca5\u6a23\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u75be\u75c5 (\u300cASCVD\u300d)\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002 \u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57 (NCT06005597) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u548c 10 mg Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5728\u60a3\u6709 HeFH \u53ca\/\u6216\u5df2\u78ba\u8a3a ASCVD \u6216\u6709\u591a\u91cd ASCVD \u98a8\u96aa\u56e0\u7d20\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u00a0 BROADWAY \u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u662f Obicetrapib 10 mg \u7d44\u76f8\u8f03\u65bc\u5b89\u6170\u5291\u7d44\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u7684\u6700\u5c0f\u4e8c\u4e58\u5e73\u5747\u503c\u3002\u4e3b\u8981\u7d42\u9ede\u9054\u5230\u7684\u7d71\u8a08\u610f\u7fa9\u6027\uff0cLDL-C \u964d\u4f4e 33% (p&lt;0.0001)\u3002          LDL-C percentage change at Day 84:\u00a0            Placebo\u00a0 (n=844)\u00a0    Obicetrapib 10 mg\u00a0 (n=1686)\u00a0    Difference         Mean    -2\u00a0%    -35\u00a0%    -33\u00a0%         Median    -4\u00a0%    -40\u00a0%    -36\u00a0%         LS mean    +3\u00a0%    -30\u00a0%    -33\u00a0%         \u89c0\u5bdf\u5230\u7684\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7684\u8b8a\u5316\uff0c\u5305\u62ec\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (\u300cHDL-C\u300d) \u7684\u5347\u9ad8\u4ee5\u53ca\u975e\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\u3001\u8102\u86cb\u767d (a)(\u300cLp(a)\u300d)\u3001\u8f09\u8102\u86cb\u767d B (\u300cApoB\u300d) \u548c\u8f09\u8102\u86cb\u767d A1 (ApoA1) \u7684\u964d\u4f4e\uff0c\u5747\u5448\u6b63\u9762\u8da8\u52e2\uff0c\u4e26\u8207\u5148\u524d\u81e8\u5e8a\u8a66\u9a57\u5831\u544a\u7684\u6578\u64da\u4e00\u81f4\u3002 \u4f5c\u70ba\u5b89\u5168\u6027\u5206\u6790\u7684\u4e00\u90e8\u5206\uff0c\u76e3\u6e2c\u4e86\u7279\u5225\u95dc\u6ce8\u7684\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6 (\u300cAE\u300d)\u3002\u5728\u9019\u4e9b AE \u4e2d\uff0c\u8840\u7cd6\u63a7\u5236\u548c\u814e\u529f\u80fd\u65b9\u9762\uff0cObicetrapib \u7d44\u5747\u512a\u65bc\u5c0d\u7167\u7d44\u3002 \u6b64\u5916\uff0cBROADWAY \u8a66\u9a57\u5c0d MACE \u9032\u884c\u4e86\u88c1\u5b9a\uff0c\u5305\u62ec\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u6027\u4e2d\u98a8\u548c\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u91cd\u5efa\u8853\uff0c\u7d50\u679c\u00a0\u986f\u793a Obicetrapib \u7d44\u7684\u9996\u500b\u56db\u9805 MACE \u4e8b\u4ef6\u767c\u751f\u7387\u964d\u4f4e\u4e86 21%\u3002          Major adverse cardiovascular events table:\u00a0            Placebo\u00a0 (n=844)\u00a0    Obicetrapib 10 mg\u00a0 (n= 1686)\u00a0    Hazard Ratio\u00a0    95% CI\u00a0         All-cause mortality \u2013 no. (%)    12 (1.4)    19 (1.1)    0.83    (0.40-1.71)         Coronary heart death \u2013 no. (%)    5 (0.6)    8 (0.5)    0.80    (0.26-2.44)         First 4-point MACE \u2013 no. (%)    44 (5.2)    70 (4.2)    0.79    (0.54-1.15)         4-point MACE: C\u00a0HD \u00a0death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization . MACE was not a primary or secondary endpoint of the BROADWAY trial.         \u7e3d\u9ad4\u800c\u8a00\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u4ea6\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\uff08\u5305\u62ec\u8840\u58d3\uff09\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002Obicetrapib \u7d44\u4e2d\u6b62\u6cbb\u7642\u7387\u70ba 11.1%\uff0c\u5b89\u6170\u5291\u7684 12.4%\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d)\u3001\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\u4ee5\u53ca\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d) \u7684\u767c\u751f\u7387\u3002             Placebo (n=8\u00a043)    Obicetrapib 10 mg (n=1\u00a0,685)         Any TEAEs \u2013 no. (%)    513 (60.9)    1007 (59.8)         Any trial drug related TEAEs \u2013 no (%)    39 (4.6)    76 (4.5)         Any TEAEs leading to discontinuation of trial drug \u2013 no. (%    43 (5.1)    68 (4.0)         Any TESAEs \u2013 no. (%)    117 (13.9)    211 (12.5)         TANDEM \u8a66\u9a57\u7684\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u70ba\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5404\u55ae\u85e5\u6cbb\u7642\u7d44\u76f8\u6bd4\uff0c\u4ee5\u53ca Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\u3002\u6b21\u8981\u7d42\u9ede\u5305\u62ec\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7531\u57fa\u7dda\u8d77\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u5305\u62ec Lp(a)\u3001\u975e HDL-c \u548c APO B\u3002 TANDEM \u8a66\u9a57\u9054\u6210\u4e86\u6240\u6709\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u5176\u4e2d\u5305\u62ec\u5728\u7b2c 84 \u5929\u6642\uff0cObicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u9054\u5230 48.6% \u7684 LS \u5e73\u5747\u964d\u5e45 (p &lt; 0.0001)\u3002 \u7b2c 84 \u5929\u7684 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u00a0             Ezetimibe\u00a0 (n = 101)\u00a0    Obicetrapib (n = 102)\u00a0    Obicetrapib and Ezetimibe FDC\u00a0 (n = 102)\u00a0         Day 84 \u2013 from placebo                  Mean %    -23.3    -35.5    -52.2         Median %    -22.6    -37.2    -54.0         LS mean %    -20.7    -31.9    -48.6         Comparison to pbo    -    (p&lt;0.0001)    (p&lt;0.0001)         Comparison to eze 10 mg    -    -    (p&lt;0.0001)         Comparison to obi 10 mg    -    -    (p = 0.0007)         \u5728\u8a72\u8a66\u9a57\u4e2d\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d) \u53ca\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d)\u3002             Placebo (n=102)\u00a0    Ezetimibe (n=101)\u00a0    Obicetrapib (n=102)\u00a0    Obicetrapib \/ Ezetimibe FDC (n=102)\u00a0         Any study drug-related TEAEs    4 (3.9\u00a0%)    3 (3.0\u00a0%)    7 (6.9\u00a0%)    3 (2.9\u00a0%)         Any study drug-related TEAEs leading to discontinuation of study drug    2 (2.0\u00a0%)    1 (1.0\u00a0%)    6 (5.9\u00a0%)    1 (1.0\u00a0%)         Any study drug related TESAEs    0 (0.0\u00a0%)    0 (0.0\u00a0%)    0 (0.0\u00a0%)    0 (0.0\u00a0%)         \u300c\u5fc3\u8840\u7ba1\u75be\u75c5 (CVD) \u662f\u5168\u7403\u4e3b\u8981\u7684\u6b7b\u4ea1\u539f\u56e0\uff0c\u4f30\u8a08\u6bcf\u5e74\u596a\u53bb 1,790 \u842c\u4eba\u7684\u751f\u547d\u3002\u5118\u7ba1\u964d\u8102\u6cbb\u7642\u5df2\u5ee3\u6cdb\u61c9\u7528\uff0c\u4f46\u8207\u5fc3\u8840\u7ba1\u75be\u75c5\u76f8\u95dc\u7684\u6b7b\u4ea1\u4eba\u6578\u6709\u6240\u4e0a\u5347\uff0c\u4e14\u60a3\u8005\u7684 LDL-C \u6c34\u5e73\u4ecd\u7136\u8d85\u51fa\u76ee\u6a19\u503c\uff0c\u8a31\u591a\u60a3\u8005\u672a\u80fd\u9054\u5230\u6307\u5f15\u5efa\u8b70\u7684 LDL-C \u76ee\u6a19\u6c34\u5e73\u3002\u60a3\u8005\u53ca\u5176\u91ab\u751f\u9700\u8981\u5176\u4ed6\u6cbb\u7642\u9078\u64c7\u3002\u6211\u5011\u975e\u5e38\u9ad8\u8208 BROADWAY \u548c TANDEM \u7684\u6578\u64da\uff0c\u4ee5\u53ca\u5148\u524d\u516c\u4f48\u7684 BROOKLYN \u6578\u64da\uff0c\u5747\u8b49\u5be6\u4e86 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u80fd\u5920\u986f\u8457\u964d\u4f4e LDL-C\uff0c\u4e26\u5e6b\u52a9\u60a3\u8005\u9054\u5230\u5efa\u8b70\u7684\u76ee\u6a19\u6c34\u5e73\u3002\u9019\u4ee3\u8868\u8457\u6211\u5011\u81f4\u529b\u65bc\u70ba\u6b50\u6d32\u5fc3\u8840\u7ba1\u75be\u75c5\u60a3\u8005\u63d0\u4f9b\u6f5b\u5728\u540c\u985e\u9996\u5275\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u6cbb\u7642\u65b9\u6848\u7684\u91cd\u8981\u91cc\u7a0b\u7891\uff0c\u9019\u4ea6\u662f\u672c\u516c\u53f8\u4e09\u5341\u591a\u5e74\u4f86\u4e00\u76f4\u79c9\u6301\u7684\u4f7f\u547d\u300d\uff0cMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u70ba\u671f 52 \u9031\u7684\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u591a\u4e2d\u5fc3\u7814\u7a76\u8a55\u4f30\u4e86 10 mg Obicetrapib \u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u4f5c\u70ba\u6700\u5927\u8010\u53d7\u964d\u8102\u7642\u6cd5\u7684\u8f14\u52a9\u5291\uff0c\u5c08\u9580\u7528\u65bc LDL-C \u7121\u6cd5\u5145\u5206\u63a7\u5236\u7684 ASCVD \u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u8a72\u7814\u7a76\u5728\u5317\u7f8e\uff0c\u6b50\u6d32\uff0c\u4e9e\u6d32\u548c\u6fb3\u6d32\u7b49\u5730\u9032\u884c\u3002\u5171 2,530 \u540d\u60a3\u8005\u88ab\u96a8\u6a5f\u5206\u70ba\u5169\u7d44\uff0c\u6bd4\u4f8b\u70ba2:1\uff0c\u63a5\u53d7\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d 10 mg Obicetrapib \u6216\u5b89\u6170\u5291\u6cbb\u7642\uff0c\u70ba\u671f 52 \u9031\uff0c\u4e26\u4e14\u4e0d\u53d7\u98df\u7269\u5f71\u97ff\u3002\u5118\u7ba1\u8fd1 70% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 Obicetrapib \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 100 mg\/dL\u3002\u5973\u6027\u7d04\u4f54\u7814\u7a76\u5c0d\u8c61\u7684 34%\uff0c\u7814\u7a76\u53c3\u8207\u8005\u57fa\u6e96\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba 65 \u6b72\u3002 \u4e3b\u8981\u7d42\u9ede\u70ba Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u7d93\u586b\u88dc\u6cd5\u5206\u6790\u986f\u793a\u964d\u4f4e\u4e86 33%\u3002\u6b21\u8981\u7d42\u9ede\u4ea6\u5305\u62ec Obicetrapib 10 mg \u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929ApoB\u3001Lp(a)\u3001ApoA1\u3001HDL-C\u3001\u975eHDL-C\u3001\u7e3d\u81bd\u56fa\u9187\u53ca\u7518\u6cb9\u4e09\u916f\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u4ee5\u53ca\u7b2c 180 \u5929\u53ca\u7b2c 365 \u5929\u7684 LDL-C \u6c34\u5e73\uff08\u5206\u5225\u964d\u4f4e 34%\u53ca 24%\uff0cp&lt;0.0001\uff09\u3002\u5176\u4ed6\u7d50\u679c\u6307\u6a19\u5305\u62ec Obicetrapib \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u96a8\u6a5f\u5206\u7d44\u81f3\u9996\u6b21\u78ba\u8a3a\u767c\u751f MACE \u7684\u6642\u9593\u3002\u8a72\u8a66\u9a57\u9084\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u6a1e\u7d10\u6027\u7b2c\u4e09\u671f\u3001\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u56db\u7d44\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5c0d LDL-C \u6c34\u5e73\u7684\u5f71\u97ff\uff0c\u4e26\u8207 10 mg ezetimibe \u53ca 10 mg Obicetrapib 10 mg \u55ae\u85e5\u6cbb\u7642\u53ca\u5b89\u6170\u5291\u9032\u884c\u6bd4\u8f03\u3002\u8a72\u7814\u7a76\u65bc\u7f8e\u570b\u5404\u5730\u7684\u591a\u500b\u7814\u7a76\u4e2d\u5fc3\u9032\u884c\uff0c\u5171\u6709 407 \u540d\u57fa\u7dda LDL-C \u81f3\u5c11\u70ba70 mg\/dL\uff0c\u4e14\u60a3\u6709 HeFH \u53ca\/\u6216 ASCVD \u6216\u5177 ASCVD \u98a8\u96aa\u7b49\u540c\u60c5\u6cc1\u7684\u60a3\u8005\uff0c\u4ee5 1:1:1:1 \u7684\u6bd4\u4f8b\u96a8\u6a5f\u5206\u914d\u63a5\u53d7 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u300110 mg Obicetrapib\u300110 mg ezetimibe\u6216 \u5b89\u6170\u5291\uff0c\u6cbb\u7642\u671f\u70ba 84 \u5929\u3002\u5118\u7ba1\u7d04 74% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 obicetrapib-ezetimibe \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 97 mg\/dL\u3002\u9664\u8a55\u4f30\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u53ca\u6b21\u8981\u7d42\u9ede\u5916\uff0c\u8a72\u8a66\u9a57\u4ea6\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u3002 Obicetrapib\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u8a08\u5283 Obicetrapib \u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u5305\u62ec\u56db\u9805\u7814\u7a76\uff0c\u6d89\u53ca\u8d85\u904e 12,250 \u540d\u60a3\u8005\u3002\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u91dd\u5c0d Obicetrapib \u55ae\u7368\u6cbb\u7642\uff0c\u4e00\u9805\u5247\u8a55\u4f30 obicetrapib \u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u7d44\u5408 (\u300cFDC\u300d)\uff1a   BROOKLYN \u8a66\u9a57 (NCT05425745) \u5c0d\u65bc\u5728 HeFH \u4e0b\u4ecd\u672a\u80fd\u5145\u5206\u63a7\u5236 LDL-C \u7684\u60a3\u8005\uff0c\u8a55\u4f30\u5176\u4f7f\u7528 Obicetrapib \u7684\u6548\u679c\u30022023 \u5e74 4 \u6708\u5b8c\u6210\u8d85\u904e 350 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024\u5e74\u7b2c\u4e09\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002  BROADWAY \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u5c0d\u65bc\u60a3\u6709\u78ba\u5b9a\u7684 ASCVD \u53ca\/\u6216 HeFH \u7684\u6210\u5e74\u60a3\u8005\u7684\u6548\u679c\u3002\u5118\u7ba1\u9019\u4e9b\u60a3\u8005\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46\u5176 LDL-C \u6c34\u5e73\u4ecd\u672a\u80fd\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT05142722)\u30022023 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 2,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74\u7b2c\u56db\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002  TANDEM \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u4f5c\u70ba FDC \u7247\u5291\u7684\u4e00\u90e8\u5206\uff0c\u7528\u65bc\u60a3\u6709 ASCVD \u6216\u591a\u7a2e ASCVD \u98a8\u96aa\u56e0\u7d20\u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u9019\u4e9b\u60a3\u8005\u5118\u7ba1\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46 LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT06005597)\u3002 2024 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 400 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74 11 \u6708\u9304\u5f97\u9802\u7dda\u6578\u64da  PREVAIL \u662f\u4e00\u9805\u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57 (\u300cCVOT\u300d)\uff0c\u65e8\u5728\u8a55\u4f30\u6709 ASCVD \u75c5\u53f2\u7684\u60a3\u8005\uff0c\u5118\u7ba1\u5df2\u63a1\u7528\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0cObicetrapib \u5c0d\u65bc\u90a3\u4e9b LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u60a3\u8005\u7684\u6548\u679c (NCT05202509)\u30022024\u5e744\u6708\u5b8c\u6210\u8d85\u904e9500\u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u3002  \u95dc\u65bc Obicetrapib Obicetrapib \u662f\u4e00\u7a2e\u65b0\u578b\u7684\u53e3\u670d\u4f4e\u5291\u91cf CETP \u6291\u5236\u5291\uff0c\u65e8\u5728\u514b\u670d\u76ee\u524d\u964d\u4f4eLDL\u6cbb\u7642\u7684\u5c40\u9650\u6027\u3002\u5728\u5404\u9805\u7b2c\u4e8c\u671f\u8a66\u9a57 ROSE2\u3001TULIP\u3001ROSE\uff0c\u4ee5\u53ca\u7b2c\u4e09\u671f\u8a66\u9a57 BROOKLYN\u3001BROADWAY \u548c TANDEM \u4e2d\uff0c\u8a55\u4f30 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u806f\u5408\u6cbb\u7642\u6642\uff0c\u5747\u89c0\u5bdf\u5230\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684 LDL-C \u964d\u4f4e\uff0c\u4e14\u5176\u526f\u4f5c\u7528\u60c5\u6cc1\u8207\u5b89\u6170\u5291\u76f8\u4f3c\u3002\u7b2c\u4e09\u671f PREVAIL \u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57\u5728 2022 \u5e74 3 \u6708\u958b\u59cb\uff0c\u65e8\u5728\u8a55\u4f30 Obicetrapib \u6e1b\u5c11\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u7684\u6f5b\u529b\uff0c\u5305\u62ec\u5fc3\u8840\u7ba1\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u4e2d\u98a8\u548c\u975e\u9078\u64c7\u6027\u51a0\u72c0\u52d5\u8108\u518d\u8840\u7ba1\u5316\u30022024 \u5e74 4 \u6708 PREVAIL \u5b8c\u6210\u8d85\u904e 9,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\uff0c\u4e26\u9032\u884c\u96a8\u6a5f\u5206\u7d44\u3002 \u95dc\u65bc Menarini Group Menarini \u662f\u4e00\u5bb6\u9818\u5148\u570b\u969b\u88fd\u85e5\u548c\u8a3a\u65b7\u696d\u754c\u7684\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 47 \u5104\u7f8e\u5143\uff0c\u64c1\u6709\u8d85\u904e 17,000 \u540d\u54e1\u5de5\u3002Menarini\u5c08\u6ce8\u65bc\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80ba\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u3001\u708e\u75c7\u548c\u6b62\u75db\u7684\u7522\u54c1\uff0c\u5c08\u6ce8\u65bc\u9ad8\u672a\u6eff\u8db3\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u548c 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u92b7\u5f80\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc NewAmsterdam NewAmsterdam Pharma\uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS\uff09\u662f\u4e00\u9593\u5f8c\u671f\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5176\u4f7f\u547d\u662f\u5728\u73fe\u6709\u5df2\u7372\u6279\u51c6\u7684\u6cbb\u7642\u65b9\u6cd5\u4e0d\u8db3\u6216\u60a3\u8005\u8010\u53d7\u6027\u4e0d\u4f73\u7684\u60c5\u6cc1\u4e0b\uff0c\u6539\u5584\u4ee3\u8b1d\u75be\u75c5\u60a3\u8005\u7684\u8b77\u7406\u3002\u6211\u5011\u81f4\u529b\u65bc\u6eff\u8db3\u5c0d\u5b89\u5168\u3001\u8010\u53d7\u6027\u826f\u597d\u4e14\u4fbf\u6377\u7684\u4f4eLDL\u6cbb\u7642\u7684\u8feb\u5207\u9700\u6c42\u3002NewAmsterdam Pharmaceuticals \u6b63\u9032\u884c\u591a\u9805\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u53e3\u670d\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u7d66\u85e5\u7684 CETP \u6291\u5236\u5291 Obicetrapib \u55ae\u7368\u4f7f\u7528\uff0c\u6216\u8207 ezetimibe \u7d44\u6210\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u4f5c\u70ba\u964d\u4f4e LDL-C \u7684\u6548\u76ca\u3002\u6b64\u7b49\u7642\u6cd5\u64ec\u4f5c\u70ba\u5df2\u63a5\u53d7\u4ed6\u6c40\u985e\u85e5\u7269\u6cbb\u7642\uff0c\u60df LDL-C \u6fc3\u5ea6\u4ecd\u504f\u9ad8\uff0c\u4e14\u5177 CVD \u98a8\u96aa\uff0c\u73fe\u6709\u7642\u6cd5\u7642\u6548\u4e0d\u5f70\u6216\u8010\u53d7\u6027\u4e0d\u826f\u7684\u60a3\u8005\u7684\u8f14\u52a9\u6cbb\u7642\u65b9\u6848\u3002\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=284618\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Menarini Group \u516c\u4f48\u8a55\u4f30 Obicetrapib \u53ca\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291 Obicetrapib \u8207 Ezetimibe 10 mg \u7684\u95dc\u9375\u6027\u7b2c\u4e09\u671f BROADWAY \u53ca TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u2014\u2014 \u5169\u9805\u95dc\u9375\u6027\u00a0\u7814\u7a76\u5747\u9054\u5230\u00a0\u4e3b\u8981\u7d42\u9ede\uff0c\u5728\u6700\u5927\u8010\u53d7\u5291\u91cf\u7684\u964d\u8102\u6cbb\u7642\u57fa\u790e\u4e0a\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (LDL-C) \u7684 LS \u5e73\u5747\u503c\u986f\u8457\u964d\u4f4e (p&lt;0.0001)\u3002  \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\uff08Obicetrapib \u55ae\u85e5\u6cbb\u7642\uff09 \u4e2d\uff0c\u7d04 50% \u7684\u00a0\u60a3\u8005 \u9054\u5230 LDL-C \u76ee\u6a19\u503c\u4f4e\u65bc 55 mg\/dL\uff1b \u800c \u00a0\u5728 TANDEM \u7814\u7a76\uff08Obicetrapib \u8207 Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff09\u4e2d\uff0c\u5247\u6709\u8d85\u904e 70% \u7684\u60a3\u8005\u9054\u5230\u76f8\u540c\u76ee\u6a19\u503c\u3002  \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\u4e2d\uff0c\u4e00\u5e74\u6642\u89c0\u5bdf\u5230 Obicetrapib \u7684\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u00a0\u6e1b\u5c11 \u4e86 21%\uff0c\u986f\u793a\u51fa Obicetrapib \u7684\u512a\u52e2  \u2014\u2014 \u65bc\u5169\u9805\u7814\u7a76\u4e2d\uff0cObicetrapib \u55ae\u85e5\u7642\u6cd5\u53ca\u8207\u00a0Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5747\u986f\u793a\u51fa\u826f\u597d\u8010\u53d7\u6027 \u00a0  \u610f\u5927\u5229\u4f5b\u7f85\u502b\u85a92024\u5e7412\u670817\u65e5 \/\u7f8e\u901a\u793e\/ -- Menarini Group\u4eca\u65e5\u516c\u4f48\u7531NewAmsterdam Pharma Company N.V. \uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS \u6216\u300cNewAmsterdam\u300d\u6216\u300c\u8a72\u516c\u53f8\u300d\uff09\u8d0a\u52a9\u7684\u7b2c\u4e09\u671fBROADWAY (NCT05142722) \u53caTANDEM (NCT06005597) \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da\u3002NewAmsterdam\u662f\u4e00\u5bb6\u5f8c\u671f\u81e8\u5e8a\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u70ba\u60a3\u6709\u9ad8\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\uff08\u300cLDL-C\u300d\uff09\u4e14\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\uff08\u300cCVD\u300d\uff09\u98a8\u96aa\uff0c\u800c\u73fe\u6709\u7642\u6cd5\u672a\u80fd\u5145\u5206\u6709\u6548\u6216\u826f\u597d\u8010\u53d7\u7684\u60a3\u8005\uff0c\u7814\u767c\u53e3\u670d\u975e\u4ed6\u6c40\u985e\u85e5\u7269\u3002 \u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57 (NCT05142722) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg\u00a0Obicetrapib \u5728\u60a3\u6709\u7570\u5408\u5b50\u5bb6\u65cf\u6027\u9ad8\u81bd\u56fa\u9187\u8840\u75c7 (\u300cHeFH\u300d) \u53ca\/\u6216\u5df2\u78ba\u8a3a\u52d5\u8108\u7ca5\u6a23\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u75be\u75c5 (\u300cASCVD\u300d)\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002 \u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57 (NCT06005597) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u548c 10 mg Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5728\u60a3\u6709 HeFH \u53ca\/\u6216\u5df2\u78ba\u8a3a ASCVD \u6216\u6709\u591a\u91cd ASCVD \u98a8\u96aa\u56e0\u7d20\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u00a0 BROADWAY \u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u662f Obicetrapib 10 mg \u7d44\u76f8\u8f03\u65bc\u5b89\u6170\u5291\u7d44\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u7684\u6700\u5c0f\u4e8c\u4e58\u5e73\u5747\u503c\u3002\u4e3b\u8981\u7d42\u9ede\u9054\u5230\u7684\u7d71\u8a08\u610f\u7fa9\u6027\uff0cLDL-C \u964d\u4f4e 33% (p&lt;0.0001)\u3002          LDL-C percentage change at Day 84:\u00a0            Placebo\u00a0 (n=844)\u00a0    Obicetrapib 10 mg\u00a0 (n=1686)\u00a0    Difference         Mean    -2\u00a0%    -35\u00a0%    -33\u00a0%         Median    -4\u00a0%    -40\u00a0%    -36\u00a0%         LS mean    +3\u00a0%    -30\u00a0%    -33\u00a0%         \u89c0\u5bdf\u5230\u7684\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7684\u8b8a\u5316\uff0c\u5305\u62ec\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (\u300cHDL-C\u300d) \u7684\u5347\u9ad8\u4ee5\u53ca\u975e\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\u3001\u8102\u86cb\u767d (a)(\u300cLp(a)\u300d)\u3001\u8f09\u8102\u86cb\u767d B (\u300cApoB\u300d) \u548c\u8f09\u8102\u86cb\u767d A1 (ApoA1) \u7684\u964d\u4f4e\uff0c\u5747\u5448\u6b63\u9762\u8da8\u52e2\uff0c\u4e26\u8207\u5148\u524d\u81e8\u5e8a\u8a66\u9a57\u5831\u544a\u7684\u6578\u64da\u4e00\u81f4\u3002 \u4f5c\u70ba\u5b89\u5168\u6027\u5206\u6790\u7684\u4e00\u90e8\u5206\uff0c\u76e3\u6e2c\u4e86\u7279\u5225\u95dc\u6ce8\u7684\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6 (\u300cAE\u300d)\u3002\u5728\u9019\u4e9b AE \u4e2d\uff0c\u8840\u7cd6\u63a7\u5236\u548c\u814e\u529f\u80fd\u65b9\u9762\uff0cObicetrapib \u7d44\u5747\u512a\u65bc\u5c0d\u7167\u7d44\u3002 \u6b64\u5916\uff0cBROADWAY \u8a66\u9a57\u5c0d MACE \u9032\u884c\u4e86\u88c1\u5b9a\uff0c\u5305\u62ec\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u6027\u4e2d\u98a8\u548c\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u91cd\u5efa\u8853\uff0c\u7d50\u679c\u00a0\u986f\u793a Obicetrapib \u7d44\u7684\u9996\u500b\u56db\u9805 MACE \u4e8b\u4ef6\u767c\u751f\u7387\u964d\u4f4e\u4e86 21%\u3002          Major adverse cardiovascular events table:\u00a0            Placebo\u00a0 (n=844)\u00a0    Obicetrapib 10 mg\u00a0 (n= 1686)\u00a0    Hazard Ratio\u00a0    95% CI\u00a0         All-cause mortality \u2013 no. (%)    12 (1.4)    19 (1.1)    0.83    (0.40-1.71)         Coronary heart death \u2013 no. (%)    5 (0.6)    8 (0.5)    0.80    (0.26-2.44)         First 4-point MACE \u2013 no. (%)    44 (5.2)    70 (4.2)    0.79    (0.54-1.15)         4-point MACE: C\u00a0HD \u00a0death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization . MACE was not a primary or secondary endpoint of the BROADWAY trial.         \u7e3d\u9ad4\u800c\u8a00\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u4ea6\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\uff08\u5305\u62ec\u8840\u58d3\uff09\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002Obicetrapib \u7d44\u4e2d\u6b62\u6cbb\u7642\u7387\u70ba 11.1%\uff0c\u5b89\u6170\u5291\u7684 12.4%\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d)\u3001\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\u4ee5\u53ca\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d) \u7684\u767c\u751f\u7387\u3002             Placebo (n=8\u00a043)    Obicetrapib 10 mg (n=1\u00a0,685)         Any TEAEs \u2013 no. (%)    513 (60.9)    1007 (59.8)         Any trial drug related TEAEs \u2013 no (%)    39 (4.6)    76 (4.5)         Any TEAEs leading to discontinuation of trial drug \u2013 no. (%    43 (5.1)    68 (4.0)         Any TESAEs \u2013 no. (%)    117 (13.9)    211 (12.5)         TANDEM \u8a66\u9a57\u7684\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u70ba\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5404\u55ae\u85e5\u6cbb\u7642\u7d44\u76f8\u6bd4\uff0c\u4ee5\u53ca Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\u3002\u6b21\u8981\u7d42\u9ede\u5305\u62ec\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7531\u57fa\u7dda\u8d77\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u5305\u62ec Lp(a)\u3001\u975e HDL-c \u548c APO B\u3002 TANDEM \u8a66\u9a57\u9054\u6210\u4e86\u6240\u6709\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u5176\u4e2d\u5305\u62ec\u5728\u7b2c 84 \u5929\u6642\uff0cObicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u9054\u5230 48.6% \u7684 LS \u5e73\u5747\u964d\u5e45 (p &lt; 0.0001)\u3002 \u7b2c 84 \u5929\u7684 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u00a0             Ezetimibe\u00a0 (n = 101)\u00a0    Obicetrapib (n = 102)\u00a0    Obicetrapib and Ezetimibe FDC\u00a0 (n = 102)\u00a0         Day 84 \u2013 from placebo                  Mean %    -23.3    -35.5    -52.2         Median %    -22.6    -37.2    -54.0         LS mean %    -20.7    -31.9    -48.6         Comparison to pbo    -    (p&lt;0.0001)    (p&lt;0.0001)         Comparison to eze 10 mg    -    -    (p&lt;0.0001)         Comparison to obi 10 mg    -    -    (p = 0.0007)         \u5728\u8a72\u8a66\u9a57\u4e2d\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d) \u53ca\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d)\u3002             Placebo (n=102)\u00a0    Ezetimibe (n=101)\u00a0    Obicetrapib (n=102)\u00a0    Obicetrapib \/ Ezetimibe FDC (n=102)\u00a0         Any study drug-related TEAEs    4 (3.9\u00a0%)    3 (3.0\u00a0%)    7 (6.9\u00a0%)    3 (2.9\u00a0%)         Any study drug-related TEAEs leading to discontinuation of study drug    2 (2.0\u00a0%)    1 (1.0\u00a0%)    6 (5.9\u00a0%)    1 (1.0\u00a0%)         Any study drug related TESAEs    0 (0.0\u00a0%)    0 (0.0\u00a0%)    0 (0.0\u00a0%)    0 (0.0\u00a0%)         \u300c\u5fc3\u8840\u7ba1\u75be\u75c5 (CVD) \u662f\u5168\u7403\u4e3b\u8981\u7684\u6b7b\u4ea1\u539f\u56e0\uff0c\u4f30\u8a08\u6bcf\u5e74\u596a\u53bb 1,790 \u842c\u4eba\u7684\u751f\u547d\u3002\u5118\u7ba1\u964d\u8102\u6cbb\u7642\u5df2\u5ee3\u6cdb\u61c9\u7528\uff0c\u4f46\u8207\u5fc3\u8840\u7ba1\u75be\u75c5\u76f8\u95dc\u7684\u6b7b\u4ea1\u4eba\u6578\u6709\u6240\u4e0a\u5347\uff0c\u4e14\u60a3\u8005\u7684 LDL-C \u6c34\u5e73\u4ecd\u7136\u8d85\u51fa\u76ee\u6a19\u503c\uff0c\u8a31\u591a\u60a3\u8005\u672a\u80fd\u9054\u5230\u6307\u5f15\u5efa\u8b70\u7684 LDL-C \u76ee\u6a19\u6c34\u5e73\u3002\u60a3\u8005\u53ca\u5176\u91ab\u751f\u9700\u8981\u5176\u4ed6\u6cbb\u7642\u9078\u64c7\u3002\u6211\u5011\u975e\u5e38\u9ad8\u8208 BROADWAY \u548c TANDEM \u7684\u6578\u64da\uff0c\u4ee5\u53ca\u5148\u524d\u516c\u4f48\u7684 BROOKLYN \u6578\u64da\uff0c\u5747\u8b49\u5be6\u4e86 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u80fd\u5920\u986f\u8457\u964d\u4f4e LDL-C\uff0c\u4e26\u5e6b\u52a9\u60a3\u8005\u9054\u5230\u5efa\u8b70\u7684\u76ee\u6a19\u6c34\u5e73\u3002\u9019\u4ee3\u8868\u8457\u6211\u5011\u81f4\u529b\u65bc\u70ba\u6b50\u6d32\u5fc3\u8840\u7ba1\u75be\u75c5\u60a3\u8005\u63d0\u4f9b\u6f5b\u5728\u540c\u985e\u9996\u5275\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u6cbb\u7642\u65b9\u6848\u7684\u91cd\u8981\u91cc\u7a0b\u7891\uff0c\u9019\u4ea6\u662f\u672c\u516c\u53f8\u4e09\u5341\u591a\u5e74\u4f86\u4e00\u76f4\u79c9\u6301\u7684\u4f7f\u547d\u300d\uff0cMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u70ba\u671f 52 \u9031\u7684\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u591a\u4e2d\u5fc3\u7814\u7a76\u8a55\u4f30\u4e86 10 mg Obicetrapib \u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u4f5c\u70ba\u6700\u5927\u8010\u53d7\u964d\u8102\u7642\u6cd5\u7684\u8f14\u52a9\u5291\uff0c\u5c08\u9580\u7528\u65bc LDL-C \u7121\u6cd5\u5145\u5206\u63a7\u5236\u7684 ASCVD \u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u8a72\u7814\u7a76\u5728\u5317\u7f8e\uff0c\u6b50\u6d32\uff0c\u4e9e\u6d32\u548c\u6fb3\u6d32\u7b49\u5730\u9032\u884c\u3002\u5171 2,530 \u540d\u60a3\u8005\u88ab\u96a8\u6a5f\u5206\u70ba\u5169\u7d44\uff0c\u6bd4\u4f8b\u70ba2:1\uff0c\u63a5\u53d7\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d 10 mg Obicetrapib \u6216\u5b89\u6170\u5291\u6cbb\u7642\uff0c\u70ba\u671f 52 \u9031\uff0c\u4e26\u4e14\u4e0d\u53d7\u98df\u7269\u5f71\u97ff\u3002\u5118\u7ba1\u8fd1 70% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 Obicetrapib \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 100 mg\/dL\u3002\u5973\u6027\u7d04\u4f54\u7814\u7a76\u5c0d\u8c61\u7684 34%\uff0c\u7814\u7a76\u53c3\u8207\u8005\u57fa\u6e96\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba 65 \u6b72\u3002 \u4e3b\u8981\u7d42\u9ede\u70ba Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u7d93\u586b\u88dc\u6cd5\u5206\u6790\u986f\u793a\u964d\u4f4e\u4e86 33%\u3002\u6b21\u8981\u7d42\u9ede\u4ea6\u5305\u62ec Obicetrapib 10 mg \u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929ApoB\u3001Lp(a)\u3001ApoA1\u3001HDL-C\u3001\u975eHDL-C\u3001\u7e3d\u81bd\u56fa\u9187\u53ca\u7518\u6cb9\u4e09\u916f\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u4ee5\u53ca\u7b2c 180 \u5929\u53ca\u7b2c 365 \u5929\u7684 LDL-C \u6c34\u5e73\uff08\u5206\u5225\u964d\u4f4e 34%\u53ca 24%\uff0cp&lt;0.0001\uff09\u3002\u5176\u4ed6\u7d50\u679c\u6307\u6a19\u5305\u62ec Obicetrapib \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u96a8\u6a5f\u5206\u7d44\u81f3\u9996\u6b21\u78ba\u8a3a\u767c\u751f MACE \u7684\u6642\u9593\u3002\u8a72\u8a66\u9a57\u9084\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u6a1e\u7d10\u6027\u7b2c\u4e09\u671f\u3001\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u56db\u7d44\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5c0d LDL-C \u6c34\u5e73\u7684\u5f71\u97ff\uff0c\u4e26\u8207 10 mg ezetimibe \u53ca 10 mg Obicetrapib 10 mg \u55ae\u85e5\u6cbb\u7642\u53ca\u5b89\u6170\u5291\u9032\u884c\u6bd4\u8f03\u3002\u8a72\u7814\u7a76\u65bc\u7f8e\u570b\u5404\u5730\u7684\u591a\u500b\u7814\u7a76\u4e2d\u5fc3\u9032\u884c\uff0c\u5171\u6709 407 \u540d\u57fa\u7dda LDL-C \u81f3\u5c11\u70ba70 mg\/dL\uff0c\u4e14\u60a3\u6709 HeFH \u53ca\/\u6216 ASCVD \u6216\u5177 ASCVD \u98a8\u96aa\u7b49\u540c\u60c5\u6cc1\u7684\u60a3\u8005\uff0c\u4ee5 1:1:1:1 \u7684\u6bd4\u4f8b\u96a8\u6a5f\u5206\u914d\u63a5\u53d7 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u300110 mg Obicetrapib\u300110 mg ezetimibe\u6216 \u5b89\u6170\u5291\uff0c\u6cbb\u7642\u671f\u70ba 84 \u5929\u3002\u5118\u7ba1\u7d04 74% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 obicetrapib-ezetimibe \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 97 mg\/dL\u3002\u9664\u8a55\u4f30\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u53ca\u6b21\u8981\u7d42\u9ede\u5916\uff0c\u8a72\u8a66\u9a57\u4ea6\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u3002 Obicetrapib\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u8a08\u5283 Obicetrapib \u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u5305\u62ec\u56db\u9805\u7814\u7a76\uff0c\u6d89\u53ca\u8d85\u904e 12,250 \u540d\u60a3\u8005\u3002\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u91dd\u5c0d Obicetrapib \u55ae\u7368\u6cbb\u7642\uff0c\u4e00\u9805\u5247\u8a55\u4f30 obicetrapib \u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u7d44\u5408 (\u300cFDC\u300d)\uff1a   BROOKLYN \u8a66\u9a57 (NCT05425745) \u5c0d\u65bc\u5728 HeFH \u4e0b\u4ecd\u672a\u80fd\u5145\u5206\u63a7\u5236 LDL-C \u7684\u60a3\u8005\uff0c\u8a55\u4f30\u5176\u4f7f\u7528 Obicetrapib \u7684\u6548\u679c\u30022023 \u5e74 4 \u6708\u5b8c\u6210\u8d85\u904e 350 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024\u5e74\u7b2c\u4e09\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002  BROADWAY \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u5c0d\u65bc\u60a3\u6709\u78ba\u5b9a\u7684 ASCVD \u53ca\/\u6216 HeFH \u7684\u6210\u5e74\u60a3\u8005\u7684\u6548\u679c\u3002\u5118\u7ba1\u9019\u4e9b\u60a3\u8005\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46\u5176 LDL-C \u6c34\u5e73\u4ecd\u672a\u80fd\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT05142722)\u30022023 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 2,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74\u7b2c\u56db\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002  TANDEM \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u4f5c\u70ba FDC \u7247\u5291\u7684\u4e00\u90e8\u5206\uff0c\u7528\u65bc\u60a3\u6709 ASCVD \u6216\u591a\u7a2e ASCVD \u98a8\u96aa\u56e0\u7d20\u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u9019\u4e9b\u60a3\u8005\u5118\u7ba1\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46 LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT06005597)\u3002 2024 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 400 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74 11 \u6708\u9304\u5f97\u9802\u7dda\u6578\u64da  PREVAIL \u662f\u4e00\u9805\u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57 (\u300cCVOT\u300d)\uff0c\u65e8\u5728\u8a55\u4f30\u6709 ASCVD \u75c5\u53f2\u7684\u60a3\u8005\uff0c\u5118\u7ba1\u5df2\u63a1\u7528\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0cObicetrapib \u5c0d\u65bc\u90a3\u4e9b LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u60a3\u8005\u7684\u6548\u679c (NCT05202509)\u30022024\u5e744\u6708\u5b8c\u6210\u8d85\u904e9500\u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u3002  \u95dc\u65bc Obicetrapib Obicetrapib \u662f\u4e00\u7a2e\u65b0\u578b\u7684\u53e3\u670d\u4f4e\u5291\u91cf CETP \u6291\u5236\u5291\uff0c\u65e8\u5728\u514b\u670d\u76ee\u524d\u964d\u4f4eLDL\u6cbb\u7642\u7684\u5c40\u9650\u6027\u3002\u5728\u5404\u9805\u7b2c\u4e8c\u671f\u8a66\u9a57 ROSE2\u3001TULIP\u3001ROSE\uff0c\u4ee5\u53ca\u7b2c\u4e09\u671f\u8a66\u9a57 BROOKLYN\u3001BROADWAY \u548c TANDEM \u4e2d\uff0c\u8a55\u4f30 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u806f\u5408\u6cbb\u7642\u6642\uff0c\u5747\u89c0\u5bdf\u5230\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684 LDL-C \u964d\u4f4e\uff0c\u4e14\u5176\u526f\u4f5c\u7528\u60c5\u6cc1\u8207\u5b89\u6170\u5291\u76f8\u4f3c\u3002\u7b2c\u4e09\u671f PREVAIL \u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57\u5728 2022 \u5e74 3 \u6708\u958b\u59cb\uff0c\u65e8\u5728\u8a55\u4f30 Obicetrapib \u6e1b\u5c11\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u7684\u6f5b\u529b\uff0c\u5305\u62ec\u5fc3\u8840\u7ba1\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u4e2d\u98a8\u548c\u975e\u9078\u64c7\u6027\u51a0\u72c0\u52d5\u8108\u518d\u8840\u7ba1\u5316\u30022024 \u5e74 4 \u6708 PREVAIL \u5b8c\u6210\u8d85\u904e 9,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\uff0c\u4e26\u9032\u884c\u96a8\u6a5f\u5206\u7d44\u3002 \u95dc\u65bc Menarini Group Menarini \u662f\u4e00\u5bb6\u9818\u5148\u570b\u969b\u88fd\u85e5\u548c\u8a3a\u65b7\u696d\u754c\u7684\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 47 \u5104\u7f8e\u5143\uff0c\u64c1\u6709\u8d85\u904e 17,000 \u540d\u54e1\u5de5\u3002Menarini\u5c08\u6ce8\u65bc\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80ba\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u3001\u708e\u75c7\u548c\u6b62\u75db\u7684\u7522\u54c1\uff0c\u5c08\u6ce8\u65bc\u9ad8\u672a\u6eff\u8db3\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u548c 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u92b7\u5f80\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc NewAmsterdam NewAmsterdam Pharma\uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS\uff09\u662f\u4e00\u9593\u5f8c\u671f\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5176\u4f7f\u547d\u662f\u5728\u73fe\u6709\u5df2\u7372\u6279\u51c6\u7684\u6cbb\u7642\u65b9\u6cd5\u4e0d\u8db3\u6216\u60a3\u8005\u8010\u53d7\u6027\u4e0d\u4f73\u7684\u60c5\u6cc1\u4e0b\uff0c\u6539\u5584\u4ee3\u8b1d\u75be\u75c5\u60a3\u8005\u7684\u8b77\u7406\u3002\u6211\u5011\u81f4\u529b\u65bc\u6eff\u8db3\u5c0d\u5b89\u5168\u3001\u8010\u53d7\u6027\u826f\u597d\u4e14\u4fbf\u6377\u7684\u4f4eLDL\u6cbb\u7642\u7684\u8feb\u5207\u9700\u6c42\u3002NewAmsterdam Pharmaceuticals \u6b63\u9032\u884c\u591a\u9805\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u53e3\u670d\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u7d66\u85e5\u7684 CETP \u6291\u5236\u5291 Obicetrapib \u55ae\u7368\u4f7f\u7528\uff0c\u6216\u8207 ezetimibe \u7d44\u6210\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u4f5c\u70ba\u964d\u4f4e LDL-C \u7684\u6548\u76ca\u3002\u6b64\u7b49\u7642\u6cd5\u64ec\u4f5c\u70ba\u5df2\u63a5\u53d7\u4ed6\u6c40\u985e\u85e5\u7269\u6cbb\u7642\uff0c\u60df LDL-C \u6fc3\u5ea6\u4ecd\u504f\u9ad8\uff0c\u4e14\u5177 CVD \u98a8\u96aa\uff0c\u73fe\u6709\u7642\u6cd5\u7642\u6548\u4e0d\u5f70\u6216\u8010\u53d7\u6027\u4e0d\u826f\u7684\u60a3\u8005\u7684\u8f14\u52a9\u6cbb\u7642\u65b9\u6848\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=284618\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-17T17:36:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"121\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"Menarini Group \u516c\u4f48\u8a55\u4f30 Obicetrapib \u53ca\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291 Obicetrapib \u8207 Ezetimibe 10 mg \u7684\u95dc\u9375\u6027\u7b2c\u4e09\u671f BROADWAY \u53ca TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da\",\"datePublished\":\"2024-12-17T17:36:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618\"},\"wordCount\":422,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618\",\"name\":\"Menarini Group \u516c\u4f48\u8a55\u4f30 Obicetrapib \u53ca\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291 Obicetrapib \u8207 Ezetimibe 10 mg \u7684\u95dc\u9375\u6027\u7b2c\u4e09\u671f BROADWAY \u53ca TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg\",\"datePublished\":\"2024-12-17T17:36:00+00:00\",\"description\":\"\u2014\u2014 \u5169\u9805\u95dc\u9375\u6027\u00a0\u7814\u7a76\u5747\u9054\u5230\u00a0\u4e3b\u8981\u7d42\u9ede\uff0c\u5728\u6700\u5927\u8010\u53d7\u5291\u91cf\u7684\u964d\u8102\u6cbb\u7642\u57fa\u790e\u4e0a\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (LDL-C) \u7684 LS \u5e73\u5747\u503c\u986f\u8457\u964d\u4f4e (p&lt;0.0001)\u3002 \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\uff08Obicetrapib \u55ae\u85e5\u6cbb\u7642\uff09 \u4e2d\uff0c\u7d04 50% \u7684\u00a0\u60a3\u8005 \u9054\u5230 LDL-C \u76ee\u6a19\u503c\u4f4e\u65bc 55 mg\\\/dL\uff1b \u800c \u00a0\u5728 TANDEM \u7814\u7a76\uff08Obicetrapib \u8207 Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff09\u4e2d\uff0c\u5247\u6709\u8d85\u904e 70% \u7684\u60a3\u8005\u9054\u5230\u76f8\u540c\u76ee\u6a19\u503c\u3002 \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\u4e2d\uff0c\u4e00\u5e74\u6642\u89c0\u5bdf\u5230 Obicetrapib \u7684\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u00a0\u6e1b\u5c11 \u4e86 21%\uff0c\u986f\u793a\u51fa Obicetrapib \u7684\u512a\u52e2 \u2014\u2014 \u65bc\u5169\u9805\u7814\u7a76\u4e2d\uff0cObicetrapib \u55ae\u85e5\u7642\u6cd5\u53ca\u8207\u00a0Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5747\u986f\u793a\u51fa\u826f\u597d\u8010\u53d7\u6027 \u00a0 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u85a92024\u5e7412\u670817\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- Menarini Group\u4eca\u65e5\u516c\u4f48\u7531NewAmsterdam Pharma Company N.V. \uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS \u6216\u300cNewAmsterdam\u300d\u6216\u300c\u8a72\u516c\u53f8\u300d\uff09\u8d0a\u52a9\u7684\u7b2c\u4e09\u671fBROADWAY (NCT05142722) \u53caTANDEM (NCT06005597) \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da\u3002NewAmsterdam\u662f\u4e00\u5bb6\u5f8c\u671f\u81e8\u5e8a\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u70ba\u60a3\u6709\u9ad8\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\uff08\u300cLDL-C\u300d\uff09\u4e14\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\uff08\u300cCVD\u300d\uff09\u98a8\u96aa\uff0c\u800c\u73fe\u6709\u7642\u6cd5\u672a\u80fd\u5145\u5206\u6709\u6548\u6216\u826f\u597d\u8010\u53d7\u7684\u60a3\u8005\uff0c\u7814\u767c\u53e3\u670d\u975e\u4ed6\u6c40\u985e\u85e5\u7269\u3002 \u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57 (NCT05142722) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg\u00a0Obicetrapib \u5728\u60a3\u6709\u7570\u5408\u5b50\u5bb6\u65cf\u6027\u9ad8\u81bd\u56fa\u9187\u8840\u75c7 (\u300cHeFH\u300d) \u53ca\\\/\u6216\u5df2\u78ba\u8a3a\u52d5\u8108\u7ca5\u6a23\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u75be\u75c5 (\u300cASCVD\u300d)\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002 \u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57 (NCT06005597) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u548c 10 mg Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5728\u60a3\u6709 HeFH \u53ca\\\/\u6216\u5df2\u78ba\u8a3a ASCVD \u6216\u6709\u591a\u91cd ASCVD \u98a8\u96aa\u56e0\u7d20\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u00a0 BROADWAY \u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u662f Obicetrapib 10 mg \u7d44\u76f8\u8f03\u65bc\u5b89\u6170\u5291\u7d44\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u7684\u6700\u5c0f\u4e8c\u4e58\u5e73\u5747\u503c\u3002\u4e3b\u8981\u7d42\u9ede\u9054\u5230\u7684\u7d71\u8a08\u610f\u7fa9\u6027\uff0cLDL-C \u964d\u4f4e 33% (p&lt;0.0001)\u3002 LDL-C percentage change at Day 84:\u00a0 Placebo\u00a0 (n=844)\u00a0 Obicetrapib 10 mg\u00a0 (n=1686)\u00a0 Difference Mean -2\u00a0% -35\u00a0% -33\u00a0% Median -4\u00a0% -40\u00a0% -36\u00a0% LS mean +3\u00a0% -30\u00a0% -33\u00a0% \u89c0\u5bdf\u5230\u7684\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7684\u8b8a\u5316\uff0c\u5305\u62ec\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (\u300cHDL-C\u300d) \u7684\u5347\u9ad8\u4ee5\u53ca\u975e\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\u3001\u8102\u86cb\u767d (a)(\u300cLp(a)\u300d)\u3001\u8f09\u8102\u86cb\u767d B (\u300cApoB\u300d) \u548c\u8f09\u8102\u86cb\u767d A1 (ApoA1) \u7684\u964d\u4f4e\uff0c\u5747\u5448\u6b63\u9762\u8da8\u52e2\uff0c\u4e26\u8207\u5148\u524d\u81e8\u5e8a\u8a66\u9a57\u5831\u544a\u7684\u6578\u64da\u4e00\u81f4\u3002 \u4f5c\u70ba\u5b89\u5168\u6027\u5206\u6790\u7684\u4e00\u90e8\u5206\uff0c\u76e3\u6e2c\u4e86\u7279\u5225\u95dc\u6ce8\u7684\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6 (\u300cAE\u300d)\u3002\u5728\u9019\u4e9b AE \u4e2d\uff0c\u8840\u7cd6\u63a7\u5236\u548c\u814e\u529f\u80fd\u65b9\u9762\uff0cObicetrapib \u7d44\u5747\u512a\u65bc\u5c0d\u7167\u7d44\u3002 \u6b64\u5916\uff0cBROADWAY \u8a66\u9a57\u5c0d MACE \u9032\u884c\u4e86\u88c1\u5b9a\uff0c\u5305\u62ec\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u6027\u4e2d\u98a8\u548c\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u91cd\u5efa\u8853\uff0c\u7d50\u679c\u00a0\u986f\u793a Obicetrapib \u7d44\u7684\u9996\u500b\u56db\u9805 MACE \u4e8b\u4ef6\u767c\u751f\u7387\u964d\u4f4e\u4e86 21%\u3002 Major adverse cardiovascular events table:\u00a0 Placebo\u00a0 (n=844)\u00a0 Obicetrapib 10 mg\u00a0 (n= 1686)\u00a0 Hazard Ratio\u00a0 95% CI\u00a0 All-cause mortality \u2013 no. (%) 12 (1.4) 19 (1.1) 0.83 (0.40-1.71) Coronary heart death \u2013 no. (%) 5 (0.6) 8 (0.5) 0.80 (0.26-2.44) First 4-point MACE \u2013 no. (%) 44 (5.2) 70 (4.2) 0.79 (0.54-1.15) 4-point MACE: C\u00a0HD \u00a0death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization . MACE was not a primary or secondary endpoint of the BROADWAY trial. \u7e3d\u9ad4\u800c\u8a00\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u4ea6\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\uff08\u5305\u62ec\u8840\u58d3\uff09\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002Obicetrapib \u7d44\u4e2d\u6b62\u6cbb\u7642\u7387\u70ba 11.1%\uff0c\u5b89\u6170\u5291\u7684 12.4%\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d)\u3001\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\u4ee5\u53ca\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d) \u7684\u767c\u751f\u7387\u3002 Placebo (n=8\u00a043) Obicetrapib 10 mg (n=1\u00a0,685) Any TEAEs \u2013 no. (%) 513 (60.9) 1007 (59.8) Any trial drug related TEAEs \u2013 no (%) 39 (4.6) 76 (4.5) Any TEAEs leading to discontinuation of trial drug \u2013 no. (% 43 (5.1) 68 (4.0) Any TESAEs \u2013 no. (%) 117 (13.9) 211 (12.5) TANDEM \u8a66\u9a57\u7684\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u70ba\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5404\u55ae\u85e5\u6cbb\u7642\u7d44\u76f8\u6bd4\uff0c\u4ee5\u53ca Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\u3002\u6b21\u8981\u7d42\u9ede\u5305\u62ec\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7531\u57fa\u7dda\u8d77\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u5305\u62ec Lp(a)\u3001\u975e HDL-c \u548c APO B\u3002 TANDEM \u8a66\u9a57\u9054\u6210\u4e86\u6240\u6709\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u5176\u4e2d\u5305\u62ec\u5728\u7b2c 84 \u5929\u6642\uff0cObicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u9054\u5230 48.6% \u7684 LS \u5e73\u5747\u964d\u5e45 (p &lt; 0.0001)\u3002 \u7b2c 84 \u5929\u7684 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u00a0 Ezetimibe\u00a0 (n = 101)\u00a0 Obicetrapib (n = 102)\u00a0 Obicetrapib and Ezetimibe FDC\u00a0 (n = 102)\u00a0 Day 84 \u2013 from placebo Mean % -23.3 -35.5 -52.2 Median % -22.6 -37.2 -54.0 LS mean % -20.7 -31.9 -48.6 Comparison to pbo - (p&lt;0.0001) (p&lt;0.0001) Comparison to eze 10 mg - - (p&lt;0.0001) Comparison to obi 10 mg - - (p = 0.0007) \u5728\u8a72\u8a66\u9a57\u4e2d\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d) \u53ca\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d)\u3002 Placebo (n=102)\u00a0 Ezetimibe (n=101)\u00a0 Obicetrapib (n=102)\u00a0 Obicetrapib \\\/ Ezetimibe FDC (n=102)\u00a0 Any study drug-related TEAEs 4 (3.9\u00a0%) 3 (3.0\u00a0%) 7 (6.9\u00a0%) 3 (2.9\u00a0%) Any study drug-related TEAEs leading to discontinuation of study drug 2 (2.0\u00a0%) 1 (1.0\u00a0%) 6 (5.9\u00a0%) 1 (1.0\u00a0%) Any study drug related TESAEs 0 (0.0\u00a0%) 0 (0.0\u00a0%) 0 (0.0\u00a0%) 0 (0.0\u00a0%) \u300c\u5fc3\u8840\u7ba1\u75be\u75c5 (CVD) \u662f\u5168\u7403\u4e3b\u8981\u7684\u6b7b\u4ea1\u539f\u56e0\uff0c\u4f30\u8a08\u6bcf\u5e74\u596a\u53bb 1,790 \u842c\u4eba\u7684\u751f\u547d\u3002\u5118\u7ba1\u964d\u8102\u6cbb\u7642\u5df2\u5ee3\u6cdb\u61c9\u7528\uff0c\u4f46\u8207\u5fc3\u8840\u7ba1\u75be\u75c5\u76f8\u95dc\u7684\u6b7b\u4ea1\u4eba\u6578\u6709\u6240\u4e0a\u5347\uff0c\u4e14\u60a3\u8005\u7684 LDL-C \u6c34\u5e73\u4ecd\u7136\u8d85\u51fa\u76ee\u6a19\u503c\uff0c\u8a31\u591a\u60a3\u8005\u672a\u80fd\u9054\u5230\u6307\u5f15\u5efa\u8b70\u7684 LDL-C \u76ee\u6a19\u6c34\u5e73\u3002\u60a3\u8005\u53ca\u5176\u91ab\u751f\u9700\u8981\u5176\u4ed6\u6cbb\u7642\u9078\u64c7\u3002\u6211\u5011\u975e\u5e38\u9ad8\u8208 BROADWAY \u548c TANDEM \u7684\u6578\u64da\uff0c\u4ee5\u53ca\u5148\u524d\u516c\u4f48\u7684 BROOKLYN \u6578\u64da\uff0c\u5747\u8b49\u5be6\u4e86 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u80fd\u5920\u986f\u8457\u964d\u4f4e LDL-C\uff0c\u4e26\u5e6b\u52a9\u60a3\u8005\u9054\u5230\u5efa\u8b70\u7684\u76ee\u6a19\u6c34\u5e73\u3002\u9019\u4ee3\u8868\u8457\u6211\u5011\u81f4\u529b\u65bc\u70ba\u6b50\u6d32\u5fc3\u8840\u7ba1\u75be\u75c5\u60a3\u8005\u63d0\u4f9b\u6f5b\u5728\u540c\u985e\u9996\u5275\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u6cbb\u7642\u65b9\u6848\u7684\u91cd\u8981\u91cc\u7a0b\u7891\uff0c\u9019\u4ea6\u662f\u672c\u516c\u53f8\u4e09\u5341\u591a\u5e74\u4f86\u4e00\u76f4\u79c9\u6301\u7684\u4f7f\u547d\u300d\uff0cMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u70ba\u671f 52 \u9031\u7684\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u591a\u4e2d\u5fc3\u7814\u7a76\u8a55\u4f30\u4e86 10 mg Obicetrapib \u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u4f5c\u70ba\u6700\u5927\u8010\u53d7\u964d\u8102\u7642\u6cd5\u7684\u8f14\u52a9\u5291\uff0c\u5c08\u9580\u7528\u65bc LDL-C \u7121\u6cd5\u5145\u5206\u63a7\u5236\u7684 ASCVD \u53ca\\\/\u6216 HeFH \u60a3\u8005\u3002\u8a72\u7814\u7a76\u5728\u5317\u7f8e\uff0c\u6b50\u6d32\uff0c\u4e9e\u6d32\u548c\u6fb3\u6d32\u7b49\u5730\u9032\u884c\u3002\u5171 2,530 \u540d\u60a3\u8005\u88ab\u96a8\u6a5f\u5206\u70ba\u5169\u7d44\uff0c\u6bd4\u4f8b\u70ba2:1\uff0c\u63a5\u53d7\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d 10 mg Obicetrapib \u6216\u5b89\u6170\u5291\u6cbb\u7642\uff0c\u70ba\u671f 52 \u9031\uff0c\u4e26\u4e14\u4e0d\u53d7\u98df\u7269\u5f71\u97ff\u3002\u5118\u7ba1\u8fd1 70% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 Obicetrapib \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 100 mg\\\/dL\u3002\u5973\u6027\u7d04\u4f54\u7814\u7a76\u5c0d\u8c61\u7684 34%\uff0c\u7814\u7a76\u53c3\u8207\u8005\u57fa\u6e96\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba 65 \u6b72\u3002 \u4e3b\u8981\u7d42\u9ede\u70ba Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u7d93\u586b\u88dc\u6cd5\u5206\u6790\u986f\u793a\u964d\u4f4e\u4e86 33%\u3002\u6b21\u8981\u7d42\u9ede\u4ea6\u5305\u62ec Obicetrapib 10 mg \u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929ApoB\u3001Lp(a)\u3001ApoA1\u3001HDL-C\u3001\u975eHDL-C\u3001\u7e3d\u81bd\u56fa\u9187\u53ca\u7518\u6cb9\u4e09\u916f\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u4ee5\u53ca\u7b2c 180 \u5929\u53ca\u7b2c 365 \u5929\u7684 LDL-C \u6c34\u5e73\uff08\u5206\u5225\u964d\u4f4e 34%\u53ca 24%\uff0cp&lt;0.0001\uff09\u3002\u5176\u4ed6\u7d50\u679c\u6307\u6a19\u5305\u62ec Obicetrapib \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u96a8\u6a5f\u5206\u7d44\u81f3\u9996\u6b21\u78ba\u8a3a\u767c\u751f MACE \u7684\u6642\u9593\u3002\u8a72\u8a66\u9a57\u9084\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u6a1e\u7d10\u6027\u7b2c\u4e09\u671f\u3001\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u56db\u7d44\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5c0d LDL-C \u6c34\u5e73\u7684\u5f71\u97ff\uff0c\u4e26\u8207 10 mg ezetimibe \u53ca 10 mg Obicetrapib 10 mg \u55ae\u85e5\u6cbb\u7642\u53ca\u5b89\u6170\u5291\u9032\u884c\u6bd4\u8f03\u3002\u8a72\u7814\u7a76\u65bc\u7f8e\u570b\u5404\u5730\u7684\u591a\u500b\u7814\u7a76\u4e2d\u5fc3\u9032\u884c\uff0c\u5171\u6709 407 \u540d\u57fa\u7dda LDL-C \u81f3\u5c11\u70ba70 mg\\\/dL\uff0c\u4e14\u60a3\u6709 HeFH \u53ca\\\/\u6216 ASCVD \u6216\u5177 ASCVD \u98a8\u96aa\u7b49\u540c\u60c5\u6cc1\u7684\u60a3\u8005\uff0c\u4ee5 1:1:1:1 \u7684\u6bd4\u4f8b\u96a8\u6a5f\u5206\u914d\u63a5\u53d7 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u300110 mg Obicetrapib\u300110 mg ezetimibe\u6216 \u5b89\u6170\u5291\uff0c\u6cbb\u7642\u671f\u70ba 84 \u5929\u3002\u5118\u7ba1\u7d04 74% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 obicetrapib-ezetimibe \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 97 mg\\\/dL\u3002\u9664\u8a55\u4f30\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u53ca\u6b21\u8981\u7d42\u9ede\u5916\uff0c\u8a72\u8a66\u9a57\u4ea6\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u3002 Obicetrapib\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u8a08\u5283 Obicetrapib \u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u5305\u62ec\u56db\u9805\u7814\u7a76\uff0c\u6d89\u53ca\u8d85\u904e 12,250 \u540d\u60a3\u8005\u3002\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u91dd\u5c0d Obicetrapib \u55ae\u7368\u6cbb\u7642\uff0c\u4e00\u9805\u5247\u8a55\u4f30 obicetrapib \u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u7d44\u5408 (\u300cFDC\u300d)\uff1a BROOKLYN \u8a66\u9a57 (NCT05425745) \u5c0d\u65bc\u5728 HeFH \u4e0b\u4ecd\u672a\u80fd\u5145\u5206\u63a7\u5236 LDL-C \u7684\u60a3\u8005\uff0c\u8a55\u4f30\u5176\u4f7f\u7528 Obicetrapib \u7684\u6548\u679c\u30022023 \u5e74 4 \u6708\u5b8c\u6210\u8d85\u904e 350 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024\u5e74\u7b2c\u4e09\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002 BROADWAY \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u5c0d\u65bc\u60a3\u6709\u78ba\u5b9a\u7684 ASCVD \u53ca\\\/\u6216 HeFH \u7684\u6210\u5e74\u60a3\u8005\u7684\u6548\u679c\u3002\u5118\u7ba1\u9019\u4e9b\u60a3\u8005\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46\u5176 LDL-C \u6c34\u5e73\u4ecd\u672a\u80fd\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT05142722)\u30022023 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 2,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74\u7b2c\u56db\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002 TANDEM \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u4f5c\u70ba FDC \u7247\u5291\u7684\u4e00\u90e8\u5206\uff0c\u7528\u65bc\u60a3\u6709 ASCVD \u6216\u591a\u7a2e ASCVD \u98a8\u96aa\u56e0\u7d20\u53ca\\\/\u6216 HeFH \u60a3\u8005\u3002\u9019\u4e9b\u60a3\u8005\u5118\u7ba1\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46 LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT06005597)\u3002 2024 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 400 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74 11 \u6708\u9304\u5f97\u9802\u7dda\u6578\u64da PREVAIL \u662f\u4e00\u9805\u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57 (\u300cCVOT\u300d)\uff0c\u65e8\u5728\u8a55\u4f30\u6709 ASCVD \u75c5\u53f2\u7684\u60a3\u8005\uff0c\u5118\u7ba1\u5df2\u63a1\u7528\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0cObicetrapib \u5c0d\u65bc\u90a3\u4e9b LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u60a3\u8005\u7684\u6548\u679c (NCT05202509)\u30022024\u5e744\u6708\u5b8c\u6210\u8d85\u904e9500\u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u3002 \u95dc\u65bc Obicetrapib Obicetrapib \u662f\u4e00\u7a2e\u65b0\u578b\u7684\u53e3\u670d\u4f4e\u5291\u91cf CETP \u6291\u5236\u5291\uff0c\u65e8\u5728\u514b\u670d\u76ee\u524d\u964d\u4f4eLDL\u6cbb\u7642\u7684\u5c40\u9650\u6027\u3002\u5728\u5404\u9805\u7b2c\u4e8c\u671f\u8a66\u9a57 ROSE2\u3001TULIP\u3001ROSE\uff0c\u4ee5\u53ca\u7b2c\u4e09\u671f\u8a66\u9a57 BROOKLYN\u3001BROADWAY \u548c TANDEM \u4e2d\uff0c\u8a55\u4f30 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u806f\u5408\u6cbb\u7642\u6642\uff0c\u5747\u89c0\u5bdf\u5230\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684 LDL-C \u964d\u4f4e\uff0c\u4e14\u5176\u526f\u4f5c\u7528\u60c5\u6cc1\u8207\u5b89\u6170\u5291\u76f8\u4f3c\u3002\u7b2c\u4e09\u671f PREVAIL \u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57\u5728 2022 \u5e74 3 \u6708\u958b\u59cb\uff0c\u65e8\u5728\u8a55\u4f30 Obicetrapib \u6e1b\u5c11\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u7684\u6f5b\u529b\uff0c\u5305\u62ec\u5fc3\u8840\u7ba1\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u4e2d\u98a8\u548c\u975e\u9078\u64c7\u6027\u51a0\u72c0\u52d5\u8108\u518d\u8840\u7ba1\u5316\u30022024 \u5e74 4 \u6708 PREVAIL \u5b8c\u6210\u8d85\u904e 9,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\uff0c\u4e26\u9032\u884c\u96a8\u6a5f\u5206\u7d44\u3002 \u95dc\u65bc Menarini Group Menarini \u662f\u4e00\u5bb6\u9818\u5148\u570b\u969b\u88fd\u85e5\u548c\u8a3a\u65b7\u696d\u754c\u7684\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 47 \u5104\u7f8e\u5143\uff0c\u64c1\u6709\u8d85\u904e 17,000 \u540d\u54e1\u5de5\u3002Menarini\u5c08\u6ce8\u65bc\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80ba\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u3001\u708e\u75c7\u548c\u6b62\u75db\u7684\u7522\u54c1\uff0c\u5c08\u6ce8\u65bc\u9ad8\u672a\u6eff\u8db3\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u548c 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u92b7\u5f80\u5168\u7403 140 \u500b\u570b\u5bb6\\\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc NewAmsterdam NewAmsterdam Pharma\uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS\uff09\u662f\u4e00\u9593\u5f8c\u671f\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5176\u4f7f\u547d\u662f\u5728\u73fe\u6709\u5df2\u7372\u6279\u51c6\u7684\u6cbb\u7642\u65b9\u6cd5\u4e0d\u8db3\u6216\u60a3\u8005\u8010\u53d7\u6027\u4e0d\u4f73\u7684\u60c5\u6cc1\u4e0b\uff0c\u6539\u5584\u4ee3\u8b1d\u75be\u75c5\u60a3\u8005\u7684\u8b77\u7406\u3002\u6211\u5011\u81f4\u529b\u65bc\u6eff\u8db3\u5c0d\u5b89\u5168\u3001\u8010\u53d7\u6027\u826f\u597d\u4e14\u4fbf\u6377\u7684\u4f4eLDL\u6cbb\u7642\u7684\u8feb\u5207\u9700\u6c42\u3002NewAmsterdam Pharmaceuticals \u6b63\u9032\u884c\u591a\u9805\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u53e3\u670d\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u7d66\u85e5\u7684 CETP \u6291\u5236\u5291 Obicetrapib \u55ae\u7368\u4f7f\u7528\uff0c\u6216\u8207 ezetimibe \u7d44\u6210\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u4f5c\u70ba\u964d\u4f4e LDL-C \u7684\u6548\u76ca\u3002\u6b64\u7b49\u7642\u6cd5\u64ec\u4f5c\u70ba\u5df2\u63a5\u53d7\u4ed6\u6c40\u985e\u85e5\u7269\u6cbb\u7642\uff0c\u60df LDL-C \u6fc3\u5ea6\u4ecd\u504f\u9ad8\uff0c\u4e14\u5177 CVD \u98a8\u96aa\uff0c\u73fe\u6709\u7642\u6cd5\u7642\u6548\u4e0d\u5f70\u6216\u8010\u53d7\u6027\u4e0d\u826f\u7684\u60a3\u8005\u7684\u8f14\u52a9\u6cbb\u7642\u65b9\u6848\u3002\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg\",\"width\":400,\"height\":121},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=284618#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Menarini Group \u516c\u4f48\u8a55\u4f30 Obicetrapib \u53ca\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291 Obicetrapib \u8207 Ezetimibe 10 mg \u7684\u95dc\u9375\u6027\u7b2c\u4e09\u671f BROADWAY \u53ca TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Menarini Group \u516c\u4f48\u8a55\u4f30 Obicetrapib \u53ca\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291 Obicetrapib \u8207 Ezetimibe 10 mg \u7684\u95dc\u9375\u6027\u7b2c\u4e09\u671f BROADWAY \u53ca TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u2014\u2014 \u5169\u9805\u95dc\u9375\u6027\u00a0\u7814\u7a76\u5747\u9054\u5230\u00a0\u4e3b\u8981\u7d42\u9ede\uff0c\u5728\u6700\u5927\u8010\u53d7\u5291\u91cf\u7684\u964d\u8102\u6cbb\u7642\u57fa\u790e\u4e0a\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (LDL-C) \u7684 LS \u5e73\u5747\u503c\u986f\u8457\u964d\u4f4e (p&lt;0.0001)\u3002  \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\uff08Obicetrapib \u55ae\u85e5\u6cbb\u7642\uff09 \u4e2d\uff0c\u7d04 50% \u7684\u00a0\u60a3\u8005 \u9054\u5230 LDL-C \u76ee\u6a19\u503c\u4f4e\u65bc 55 mg\/dL\uff1b \u800c \u00a0\u5728 TANDEM \u7814\u7a76\uff08Obicetrapib \u8207 Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff09\u4e2d\uff0c\u5247\u6709\u8d85\u904e 70% \u7684\u60a3\u8005\u9054\u5230\u76f8\u540c\u76ee\u6a19\u503c\u3002  \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\u4e2d\uff0c\u4e00\u5e74\u6642\u89c0\u5bdf\u5230 Obicetrapib \u7684\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u00a0\u6e1b\u5c11 \u4e86 21%\uff0c\u986f\u793a\u51fa Obicetrapib \u7684\u512a\u52e2  \u2014\u2014 \u65bc\u5169\u9805\u7814\u7a76\u4e2d\uff0cObicetrapib \u55ae\u85e5\u7642\u6cd5\u53ca\u8207\u00a0Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5747\u986f\u793a\u51fa\u826f\u597d\u8010\u53d7\u6027 \u00a0  \u610f\u5927\u5229\u4f5b\u7f85\u502b\u85a92024\u5e7412\u670817\u65e5 \/\u7f8e\u901a\u793e\/ -- Menarini Group\u4eca\u65e5\u516c\u4f48\u7531NewAmsterdam Pharma Company N.V. \uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS \u6216\u300cNewAmsterdam\u300d\u6216\u300c\u8a72\u516c\u53f8\u300d\uff09\u8d0a\u52a9\u7684\u7b2c\u4e09\u671fBROADWAY (NCT05142722) \u53caTANDEM (NCT06005597) \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da\u3002NewAmsterdam\u662f\u4e00\u5bb6\u5f8c\u671f\u81e8\u5e8a\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u70ba\u60a3\u6709\u9ad8\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\uff08\u300cLDL-C\u300d\uff09\u4e14\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\uff08\u300cCVD\u300d\uff09\u98a8\u96aa\uff0c\u800c\u73fe\u6709\u7642\u6cd5\u672a\u80fd\u5145\u5206\u6709\u6548\u6216\u826f\u597d\u8010\u53d7\u7684\u60a3\u8005\uff0c\u7814\u767c\u53e3\u670d\u975e\u4ed6\u6c40\u985e\u85e5\u7269\u3002 \u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57 (NCT05142722) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg\u00a0Obicetrapib \u5728\u60a3\u6709\u7570\u5408\u5b50\u5bb6\u65cf\u6027\u9ad8\u81bd\u56fa\u9187\u8840\u75c7 (\u300cHeFH\u300d) \u53ca\/\u6216\u5df2\u78ba\u8a3a\u52d5\u8108\u7ca5\u6a23\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u75be\u75c5 (\u300cASCVD\u300d)\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002 \u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57 (NCT06005597) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u548c 10 mg Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5728\u60a3\u6709 HeFH \u53ca\/\u6216\u5df2\u78ba\u8a3a ASCVD \u6216\u6709\u591a\u91cd ASCVD \u98a8\u96aa\u56e0\u7d20\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u00a0 BROADWAY \u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u662f Obicetrapib 10 mg \u7d44\u76f8\u8f03\u65bc\u5b89\u6170\u5291\u7d44\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u7684\u6700\u5c0f\u4e8c\u4e58\u5e73\u5747\u503c\u3002\u4e3b\u8981\u7d42\u9ede\u9054\u5230\u7684\u7d71\u8a08\u610f\u7fa9\u6027\uff0cLDL-C \u964d\u4f4e 33% (p&lt;0.0001)\u3002          LDL-C percentage change at Day 84:\u00a0            Placebo\u00a0 (n=844)\u00a0    Obicetrapib 10 mg\u00a0 (n=1686)\u00a0    Difference         Mean    -2\u00a0%    -35\u00a0%    -33\u00a0%         Median    -4\u00a0%    -40\u00a0%    -36\u00a0%         LS mean    +3\u00a0%    -30\u00a0%    -33\u00a0%         \u89c0\u5bdf\u5230\u7684\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7684\u8b8a\u5316\uff0c\u5305\u62ec\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (\u300cHDL-C\u300d) \u7684\u5347\u9ad8\u4ee5\u53ca\u975e\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\u3001\u8102\u86cb\u767d (a)(\u300cLp(a)\u300d)\u3001\u8f09\u8102\u86cb\u767d B (\u300cApoB\u300d) \u548c\u8f09\u8102\u86cb\u767d A1 (ApoA1) \u7684\u964d\u4f4e\uff0c\u5747\u5448\u6b63\u9762\u8da8\u52e2\uff0c\u4e26\u8207\u5148\u524d\u81e8\u5e8a\u8a66\u9a57\u5831\u544a\u7684\u6578\u64da\u4e00\u81f4\u3002 \u4f5c\u70ba\u5b89\u5168\u6027\u5206\u6790\u7684\u4e00\u90e8\u5206\uff0c\u76e3\u6e2c\u4e86\u7279\u5225\u95dc\u6ce8\u7684\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6 (\u300cAE\u300d)\u3002\u5728\u9019\u4e9b AE \u4e2d\uff0c\u8840\u7cd6\u63a7\u5236\u548c\u814e\u529f\u80fd\u65b9\u9762\uff0cObicetrapib \u7d44\u5747\u512a\u65bc\u5c0d\u7167\u7d44\u3002 \u6b64\u5916\uff0cBROADWAY \u8a66\u9a57\u5c0d MACE \u9032\u884c\u4e86\u88c1\u5b9a\uff0c\u5305\u62ec\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u6027\u4e2d\u98a8\u548c\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u91cd\u5efa\u8853\uff0c\u7d50\u679c\u00a0\u986f\u793a Obicetrapib \u7d44\u7684\u9996\u500b\u56db\u9805 MACE \u4e8b\u4ef6\u767c\u751f\u7387\u964d\u4f4e\u4e86 21%\u3002          Major adverse cardiovascular events table:\u00a0            Placebo\u00a0 (n=844)\u00a0    Obicetrapib 10 mg\u00a0 (n= 1686)\u00a0    Hazard Ratio\u00a0    95% CI\u00a0         All-cause mortality \u2013 no. (%)    12 (1.4)    19 (1.1)    0.83    (0.40-1.71)         Coronary heart death \u2013 no. (%)    5 (0.6)    8 (0.5)    0.80    (0.26-2.44)         First 4-point MACE \u2013 no. (%)    44 (5.2)    70 (4.2)    0.79    (0.54-1.15)         4-point MACE: C\u00a0HD \u00a0death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization . MACE was not a primary or secondary endpoint of the BROADWAY trial.         \u7e3d\u9ad4\u800c\u8a00\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u4ea6\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\uff08\u5305\u62ec\u8840\u58d3\uff09\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002Obicetrapib \u7d44\u4e2d\u6b62\u6cbb\u7642\u7387\u70ba 11.1%\uff0c\u5b89\u6170\u5291\u7684 12.4%\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d)\u3001\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\u4ee5\u53ca\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d) \u7684\u767c\u751f\u7387\u3002             Placebo (n=8\u00a043)    Obicetrapib 10 mg (n=1\u00a0,685)         Any TEAEs \u2013 no. (%)    513 (60.9)    1007 (59.8)         Any trial drug related TEAEs \u2013 no (%)    39 (4.6)    76 (4.5)         Any TEAEs leading to discontinuation of trial drug \u2013 no. (%    43 (5.1)    68 (4.0)         Any TESAEs \u2013 no. (%)    117 (13.9)    211 (12.5)         TANDEM \u8a66\u9a57\u7684\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u70ba\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5404\u55ae\u85e5\u6cbb\u7642\u7d44\u76f8\u6bd4\uff0c\u4ee5\u53ca Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\u3002\u6b21\u8981\u7d42\u9ede\u5305\u62ec\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7531\u57fa\u7dda\u8d77\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u5305\u62ec Lp(a)\u3001\u975e HDL-c \u548c APO B\u3002 TANDEM \u8a66\u9a57\u9054\u6210\u4e86\u6240\u6709\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u5176\u4e2d\u5305\u62ec\u5728\u7b2c 84 \u5929\u6642\uff0cObicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u9054\u5230 48.6% \u7684 LS \u5e73\u5747\u964d\u5e45 (p &lt; 0.0001)\u3002 \u7b2c 84 \u5929\u7684 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u00a0             Ezetimibe\u00a0 (n = 101)\u00a0    Obicetrapib (n = 102)\u00a0    Obicetrapib and Ezetimibe FDC\u00a0 (n = 102)\u00a0         Day 84 \u2013 from placebo                  Mean %    -23.3    -35.5    -52.2         Median %    -22.6    -37.2    -54.0         LS mean %    -20.7    -31.9    -48.6         Comparison to pbo    -    (p&lt;0.0001)    (p&lt;0.0001)         Comparison to eze 10 mg    -    -    (p&lt;0.0001)         Comparison to obi 10 mg    -    -    (p = 0.0007)         \u5728\u8a72\u8a66\u9a57\u4e2d\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d) \u53ca\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d)\u3002             Placebo (n=102)\u00a0    Ezetimibe (n=101)\u00a0    Obicetrapib (n=102)\u00a0    Obicetrapib \/ Ezetimibe FDC (n=102)\u00a0         Any study drug-related TEAEs    4 (3.9\u00a0%)    3 (3.0\u00a0%)    7 (6.9\u00a0%)    3 (2.9\u00a0%)         Any study drug-related TEAEs leading to discontinuation of study drug    2 (2.0\u00a0%)    1 (1.0\u00a0%)    6 (5.9\u00a0%)    1 (1.0\u00a0%)         Any study drug related TESAEs    0 (0.0\u00a0%)    0 (0.0\u00a0%)    0 (0.0\u00a0%)    0 (0.0\u00a0%)         \u300c\u5fc3\u8840\u7ba1\u75be\u75c5 (CVD) \u662f\u5168\u7403\u4e3b\u8981\u7684\u6b7b\u4ea1\u539f\u56e0\uff0c\u4f30\u8a08\u6bcf\u5e74\u596a\u53bb 1,790 \u842c\u4eba\u7684\u751f\u547d\u3002\u5118\u7ba1\u964d\u8102\u6cbb\u7642\u5df2\u5ee3\u6cdb\u61c9\u7528\uff0c\u4f46\u8207\u5fc3\u8840\u7ba1\u75be\u75c5\u76f8\u95dc\u7684\u6b7b\u4ea1\u4eba\u6578\u6709\u6240\u4e0a\u5347\uff0c\u4e14\u60a3\u8005\u7684 LDL-C \u6c34\u5e73\u4ecd\u7136\u8d85\u51fa\u76ee\u6a19\u503c\uff0c\u8a31\u591a\u60a3\u8005\u672a\u80fd\u9054\u5230\u6307\u5f15\u5efa\u8b70\u7684 LDL-C \u76ee\u6a19\u6c34\u5e73\u3002\u60a3\u8005\u53ca\u5176\u91ab\u751f\u9700\u8981\u5176\u4ed6\u6cbb\u7642\u9078\u64c7\u3002\u6211\u5011\u975e\u5e38\u9ad8\u8208 BROADWAY \u548c TANDEM \u7684\u6578\u64da\uff0c\u4ee5\u53ca\u5148\u524d\u516c\u4f48\u7684 BROOKLYN \u6578\u64da\uff0c\u5747\u8b49\u5be6\u4e86 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u80fd\u5920\u986f\u8457\u964d\u4f4e LDL-C\uff0c\u4e26\u5e6b\u52a9\u60a3\u8005\u9054\u5230\u5efa\u8b70\u7684\u76ee\u6a19\u6c34\u5e73\u3002\u9019\u4ee3\u8868\u8457\u6211\u5011\u81f4\u529b\u65bc\u70ba\u6b50\u6d32\u5fc3\u8840\u7ba1\u75be\u75c5\u60a3\u8005\u63d0\u4f9b\u6f5b\u5728\u540c\u985e\u9996\u5275\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u6cbb\u7642\u65b9\u6848\u7684\u91cd\u8981\u91cc\u7a0b\u7891\uff0c\u9019\u4ea6\u662f\u672c\u516c\u53f8\u4e09\u5341\u591a\u5e74\u4f86\u4e00\u76f4\u79c9\u6301\u7684\u4f7f\u547d\u300d\uff0cMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u70ba\u671f 52 \u9031\u7684\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u591a\u4e2d\u5fc3\u7814\u7a76\u8a55\u4f30\u4e86 10 mg Obicetrapib \u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u4f5c\u70ba\u6700\u5927\u8010\u53d7\u964d\u8102\u7642\u6cd5\u7684\u8f14\u52a9\u5291\uff0c\u5c08\u9580\u7528\u65bc LDL-C \u7121\u6cd5\u5145\u5206\u63a7\u5236\u7684 ASCVD \u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u8a72\u7814\u7a76\u5728\u5317\u7f8e\uff0c\u6b50\u6d32\uff0c\u4e9e\u6d32\u548c\u6fb3\u6d32\u7b49\u5730\u9032\u884c\u3002\u5171 2,530 \u540d\u60a3\u8005\u88ab\u96a8\u6a5f\u5206\u70ba\u5169\u7d44\uff0c\u6bd4\u4f8b\u70ba2:1\uff0c\u63a5\u53d7\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d 10 mg Obicetrapib \u6216\u5b89\u6170\u5291\u6cbb\u7642\uff0c\u70ba\u671f 52 \u9031\uff0c\u4e26\u4e14\u4e0d\u53d7\u98df\u7269\u5f71\u97ff\u3002\u5118\u7ba1\u8fd1 70% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 Obicetrapib \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 100 mg\/dL\u3002\u5973\u6027\u7d04\u4f54\u7814\u7a76\u5c0d\u8c61\u7684 34%\uff0c\u7814\u7a76\u53c3\u8207\u8005\u57fa\u6e96\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba 65 \u6b72\u3002 \u4e3b\u8981\u7d42\u9ede\u70ba Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u7d93\u586b\u88dc\u6cd5\u5206\u6790\u986f\u793a\u964d\u4f4e\u4e86 33%\u3002\u6b21\u8981\u7d42\u9ede\u4ea6\u5305\u62ec Obicetrapib 10 mg \u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929ApoB\u3001Lp(a)\u3001ApoA1\u3001HDL-C\u3001\u975eHDL-C\u3001\u7e3d\u81bd\u56fa\u9187\u53ca\u7518\u6cb9\u4e09\u916f\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u4ee5\u53ca\u7b2c 180 \u5929\u53ca\u7b2c 365 \u5929\u7684 LDL-C \u6c34\u5e73\uff08\u5206\u5225\u964d\u4f4e 34%\u53ca 24%\uff0cp&lt;0.0001\uff09\u3002\u5176\u4ed6\u7d50\u679c\u6307\u6a19\u5305\u62ec Obicetrapib \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u96a8\u6a5f\u5206\u7d44\u81f3\u9996\u6b21\u78ba\u8a3a\u767c\u751f MACE \u7684\u6642\u9593\u3002\u8a72\u8a66\u9a57\u9084\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u6a1e\u7d10\u6027\u7b2c\u4e09\u671f\u3001\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u56db\u7d44\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5c0d LDL-C \u6c34\u5e73\u7684\u5f71\u97ff\uff0c\u4e26\u8207 10 mg ezetimibe \u53ca 10 mg Obicetrapib 10 mg \u55ae\u85e5\u6cbb\u7642\u53ca\u5b89\u6170\u5291\u9032\u884c\u6bd4\u8f03\u3002\u8a72\u7814\u7a76\u65bc\u7f8e\u570b\u5404\u5730\u7684\u591a\u500b\u7814\u7a76\u4e2d\u5fc3\u9032\u884c\uff0c\u5171\u6709 407 \u540d\u57fa\u7dda LDL-C \u81f3\u5c11\u70ba70 mg\/dL\uff0c\u4e14\u60a3\u6709 HeFH \u53ca\/\u6216 ASCVD \u6216\u5177 ASCVD \u98a8\u96aa\u7b49\u540c\u60c5\u6cc1\u7684\u60a3\u8005\uff0c\u4ee5 1:1:1:1 \u7684\u6bd4\u4f8b\u96a8\u6a5f\u5206\u914d\u63a5\u53d7 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u300110 mg Obicetrapib\u300110 mg ezetimibe\u6216 \u5b89\u6170\u5291\uff0c\u6cbb\u7642\u671f\u70ba 84 \u5929\u3002\u5118\u7ba1\u7d04 74% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 obicetrapib-ezetimibe \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 97 mg\/dL\u3002\u9664\u8a55\u4f30\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u53ca\u6b21\u8981\u7d42\u9ede\u5916\uff0c\u8a72\u8a66\u9a57\u4ea6\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u3002 Obicetrapib\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u8a08\u5283 Obicetrapib \u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u5305\u62ec\u56db\u9805\u7814\u7a76\uff0c\u6d89\u53ca\u8d85\u904e 12,250 \u540d\u60a3\u8005\u3002\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u91dd\u5c0d Obicetrapib \u55ae\u7368\u6cbb\u7642\uff0c\u4e00\u9805\u5247\u8a55\u4f30 obicetrapib \u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u7d44\u5408 (\u300cFDC\u300d)\uff1a   BROOKLYN \u8a66\u9a57 (NCT05425745) \u5c0d\u65bc\u5728 HeFH \u4e0b\u4ecd\u672a\u80fd\u5145\u5206\u63a7\u5236 LDL-C \u7684\u60a3\u8005\uff0c\u8a55\u4f30\u5176\u4f7f\u7528 Obicetrapib \u7684\u6548\u679c\u30022023 \u5e74 4 \u6708\u5b8c\u6210\u8d85\u904e 350 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024\u5e74\u7b2c\u4e09\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002  BROADWAY \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u5c0d\u65bc\u60a3\u6709\u78ba\u5b9a\u7684 ASCVD \u53ca\/\u6216 HeFH \u7684\u6210\u5e74\u60a3\u8005\u7684\u6548\u679c\u3002\u5118\u7ba1\u9019\u4e9b\u60a3\u8005\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46\u5176 LDL-C \u6c34\u5e73\u4ecd\u672a\u80fd\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT05142722)\u30022023 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 2,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74\u7b2c\u56db\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002  TANDEM \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u4f5c\u70ba FDC \u7247\u5291\u7684\u4e00\u90e8\u5206\uff0c\u7528\u65bc\u60a3\u6709 ASCVD \u6216\u591a\u7a2e ASCVD \u98a8\u96aa\u56e0\u7d20\u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u9019\u4e9b\u60a3\u8005\u5118\u7ba1\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46 LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT06005597)\u3002 2024 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 400 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74 11 \u6708\u9304\u5f97\u9802\u7dda\u6578\u64da  PREVAIL \u662f\u4e00\u9805\u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57 (\u300cCVOT\u300d)\uff0c\u65e8\u5728\u8a55\u4f30\u6709 ASCVD \u75c5\u53f2\u7684\u60a3\u8005\uff0c\u5118\u7ba1\u5df2\u63a1\u7528\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0cObicetrapib \u5c0d\u65bc\u90a3\u4e9b LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u60a3\u8005\u7684\u6548\u679c (NCT05202509)\u30022024\u5e744\u6708\u5b8c\u6210\u8d85\u904e9500\u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u3002  \u95dc\u65bc Obicetrapib Obicetrapib \u662f\u4e00\u7a2e\u65b0\u578b\u7684\u53e3\u670d\u4f4e\u5291\u91cf CETP \u6291\u5236\u5291\uff0c\u65e8\u5728\u514b\u670d\u76ee\u524d\u964d\u4f4eLDL\u6cbb\u7642\u7684\u5c40\u9650\u6027\u3002\u5728\u5404\u9805\u7b2c\u4e8c\u671f\u8a66\u9a57 ROSE2\u3001TULIP\u3001ROSE\uff0c\u4ee5\u53ca\u7b2c\u4e09\u671f\u8a66\u9a57 BROOKLYN\u3001BROADWAY \u548c TANDEM \u4e2d\uff0c\u8a55\u4f30 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u806f\u5408\u6cbb\u7642\u6642\uff0c\u5747\u89c0\u5bdf\u5230\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684 LDL-C \u964d\u4f4e\uff0c\u4e14\u5176\u526f\u4f5c\u7528\u60c5\u6cc1\u8207\u5b89\u6170\u5291\u76f8\u4f3c\u3002\u7b2c\u4e09\u671f PREVAIL \u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57\u5728 2022 \u5e74 3 \u6708\u958b\u59cb\uff0c\u65e8\u5728\u8a55\u4f30 Obicetrapib \u6e1b\u5c11\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u7684\u6f5b\u529b\uff0c\u5305\u62ec\u5fc3\u8840\u7ba1\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u4e2d\u98a8\u548c\u975e\u9078\u64c7\u6027\u51a0\u72c0\u52d5\u8108\u518d\u8840\u7ba1\u5316\u30022024 \u5e74 4 \u6708 PREVAIL \u5b8c\u6210\u8d85\u904e 9,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\uff0c\u4e26\u9032\u884c\u96a8\u6a5f\u5206\u7d44\u3002 \u95dc\u65bc Menarini Group Menarini \u662f\u4e00\u5bb6\u9818\u5148\u570b\u969b\u88fd\u85e5\u548c\u8a3a\u65b7\u696d\u754c\u7684\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 47 \u5104\u7f8e\u5143\uff0c\u64c1\u6709\u8d85\u904e 17,000 \u540d\u54e1\u5de5\u3002Menarini\u5c08\u6ce8\u65bc\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80ba\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u3001\u708e\u75c7\u548c\u6b62\u75db\u7684\u7522\u54c1\uff0c\u5c08\u6ce8\u65bc\u9ad8\u672a\u6eff\u8db3\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u548c 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u92b7\u5f80\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc NewAmsterdam NewAmsterdam Pharma\uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS\uff09\u662f\u4e00\u9593\u5f8c\u671f\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5176\u4f7f\u547d\u662f\u5728\u73fe\u6709\u5df2\u7372\u6279\u51c6\u7684\u6cbb\u7642\u65b9\u6cd5\u4e0d\u8db3\u6216\u60a3\u8005\u8010\u53d7\u6027\u4e0d\u4f73\u7684\u60c5\u6cc1\u4e0b\uff0c\u6539\u5584\u4ee3\u8b1d\u75be\u75c5\u60a3\u8005\u7684\u8b77\u7406\u3002\u6211\u5011\u81f4\u529b\u65bc\u6eff\u8db3\u5c0d\u5b89\u5168\u3001\u8010\u53d7\u6027\u826f\u597d\u4e14\u4fbf\u6377\u7684\u4f4eLDL\u6cbb\u7642\u7684\u8feb\u5207\u9700\u6c42\u3002NewAmsterdam Pharmaceuticals \u6b63\u9032\u884c\u591a\u9805\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u53e3\u670d\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u7d66\u85e5\u7684 CETP \u6291\u5236\u5291 Obicetrapib \u55ae\u7368\u4f7f\u7528\uff0c\u6216\u8207 ezetimibe \u7d44\u6210\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u4f5c\u70ba\u964d\u4f4e LDL-C \u7684\u6548\u76ca\u3002\u6b64\u7b49\u7642\u6cd5\u64ec\u4f5c\u70ba\u5df2\u63a5\u53d7\u4ed6\u6c40\u985e\u85e5\u7269\u6cbb\u7642\uff0c\u60df LDL-C \u6fc3\u5ea6\u4ecd\u504f\u9ad8\uff0c\u4e14\u5177 CVD \u98a8\u96aa\uff0c\u73fe\u6709\u7642\u6cd5\u7642\u6548\u4e0d\u5f70\u6216\u8010\u53d7\u6027\u4e0d\u826f\u7684\u60a3\u8005\u7684\u8f14\u52a9\u6cbb\u7642\u65b9\u6848\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=284618","og_locale":"zh_TW","og_type":"article","og_title":"Menarini Group \u516c\u4f48\u8a55\u4f30 Obicetrapib \u53ca\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291 Obicetrapib \u8207 Ezetimibe 10 mg \u7684\u95dc\u9375\u6027\u7b2c\u4e09\u671f BROADWAY \u53ca TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u2014\u2014 \u5169\u9805\u95dc\u9375\u6027\u00a0\u7814\u7a76\u5747\u9054\u5230\u00a0\u4e3b\u8981\u7d42\u9ede\uff0c\u5728\u6700\u5927\u8010\u53d7\u5291\u91cf\u7684\u964d\u8102\u6cbb\u7642\u57fa\u790e\u4e0a\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (LDL-C) \u7684 LS \u5e73\u5747\u503c\u986f\u8457\u964d\u4f4e (p&lt;0.0001)\u3002  \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\uff08Obicetrapib \u55ae\u85e5\u6cbb\u7642\uff09 \u4e2d\uff0c\u7d04 50% \u7684\u00a0\u60a3\u8005 \u9054\u5230 LDL-C \u76ee\u6a19\u503c\u4f4e\u65bc 55 mg\/dL\uff1b \u800c \u00a0\u5728 TANDEM \u7814\u7a76\uff08Obicetrapib \u8207 Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff09\u4e2d\uff0c\u5247\u6709\u8d85\u904e 70% \u7684\u60a3\u8005\u9054\u5230\u76f8\u540c\u76ee\u6a19\u503c\u3002  \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\u4e2d\uff0c\u4e00\u5e74\u6642\u89c0\u5bdf\u5230 Obicetrapib \u7684\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u00a0\u6e1b\u5c11 \u4e86 21%\uff0c\u986f\u793a\u51fa Obicetrapib \u7684\u512a\u52e2  \u2014\u2014 \u65bc\u5169\u9805\u7814\u7a76\u4e2d\uff0cObicetrapib \u55ae\u85e5\u7642\u6cd5\u53ca\u8207\u00a0Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5747\u986f\u793a\u51fa\u826f\u597d\u8010\u53d7\u6027 \u00a0  \u610f\u5927\u5229\u4f5b\u7f85\u502b\u85a92024\u5e7412\u670817\u65e5 \/\u7f8e\u901a\u793e\/ -- Menarini Group\u4eca\u65e5\u516c\u4f48\u7531NewAmsterdam Pharma Company N.V. \uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS \u6216\u300cNewAmsterdam\u300d\u6216\u300c\u8a72\u516c\u53f8\u300d\uff09\u8d0a\u52a9\u7684\u7b2c\u4e09\u671fBROADWAY (NCT05142722) \u53caTANDEM (NCT06005597) \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da\u3002NewAmsterdam\u662f\u4e00\u5bb6\u5f8c\u671f\u81e8\u5e8a\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u70ba\u60a3\u6709\u9ad8\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\uff08\u300cLDL-C\u300d\uff09\u4e14\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\uff08\u300cCVD\u300d\uff09\u98a8\u96aa\uff0c\u800c\u73fe\u6709\u7642\u6cd5\u672a\u80fd\u5145\u5206\u6709\u6548\u6216\u826f\u597d\u8010\u53d7\u7684\u60a3\u8005\uff0c\u7814\u767c\u53e3\u670d\u975e\u4ed6\u6c40\u985e\u85e5\u7269\u3002 \u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57 (NCT05142722) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg\u00a0Obicetrapib \u5728\u60a3\u6709\u7570\u5408\u5b50\u5bb6\u65cf\u6027\u9ad8\u81bd\u56fa\u9187\u8840\u75c7 (\u300cHeFH\u300d) \u53ca\/\u6216\u5df2\u78ba\u8a3a\u52d5\u8108\u7ca5\u6a23\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u75be\u75c5 (\u300cASCVD\u300d)\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002 \u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57 (NCT06005597) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u548c 10 mg Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5728\u60a3\u6709 HeFH \u53ca\/\u6216\u5df2\u78ba\u8a3a ASCVD \u6216\u6709\u591a\u91cd ASCVD \u98a8\u96aa\u56e0\u7d20\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u00a0 BROADWAY \u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u662f Obicetrapib 10 mg \u7d44\u76f8\u8f03\u65bc\u5b89\u6170\u5291\u7d44\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u7684\u6700\u5c0f\u4e8c\u4e58\u5e73\u5747\u503c\u3002\u4e3b\u8981\u7d42\u9ede\u9054\u5230\u7684\u7d71\u8a08\u610f\u7fa9\u6027\uff0cLDL-C \u964d\u4f4e 33% (p&lt;0.0001)\u3002          LDL-C percentage change at Day 84:\u00a0            Placebo\u00a0 (n=844)\u00a0    Obicetrapib 10 mg\u00a0 (n=1686)\u00a0    Difference         Mean    -2\u00a0%    -35\u00a0%    -33\u00a0%         Median    -4\u00a0%    -40\u00a0%    -36\u00a0%         LS mean    +3\u00a0%    -30\u00a0%    -33\u00a0%         \u89c0\u5bdf\u5230\u7684\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7684\u8b8a\u5316\uff0c\u5305\u62ec\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (\u300cHDL-C\u300d) \u7684\u5347\u9ad8\u4ee5\u53ca\u975e\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\u3001\u8102\u86cb\u767d (a)(\u300cLp(a)\u300d)\u3001\u8f09\u8102\u86cb\u767d B (\u300cApoB\u300d) \u548c\u8f09\u8102\u86cb\u767d A1 (ApoA1) \u7684\u964d\u4f4e\uff0c\u5747\u5448\u6b63\u9762\u8da8\u52e2\uff0c\u4e26\u8207\u5148\u524d\u81e8\u5e8a\u8a66\u9a57\u5831\u544a\u7684\u6578\u64da\u4e00\u81f4\u3002 \u4f5c\u70ba\u5b89\u5168\u6027\u5206\u6790\u7684\u4e00\u90e8\u5206\uff0c\u76e3\u6e2c\u4e86\u7279\u5225\u95dc\u6ce8\u7684\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6 (\u300cAE\u300d)\u3002\u5728\u9019\u4e9b AE \u4e2d\uff0c\u8840\u7cd6\u63a7\u5236\u548c\u814e\u529f\u80fd\u65b9\u9762\uff0cObicetrapib \u7d44\u5747\u512a\u65bc\u5c0d\u7167\u7d44\u3002 \u6b64\u5916\uff0cBROADWAY \u8a66\u9a57\u5c0d MACE \u9032\u884c\u4e86\u88c1\u5b9a\uff0c\u5305\u62ec\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u6027\u4e2d\u98a8\u548c\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u91cd\u5efa\u8853\uff0c\u7d50\u679c\u00a0\u986f\u793a Obicetrapib \u7d44\u7684\u9996\u500b\u56db\u9805 MACE \u4e8b\u4ef6\u767c\u751f\u7387\u964d\u4f4e\u4e86 21%\u3002          Major adverse cardiovascular events table:\u00a0            Placebo\u00a0 (n=844)\u00a0    Obicetrapib 10 mg\u00a0 (n= 1686)\u00a0    Hazard Ratio\u00a0    95% CI\u00a0         All-cause mortality \u2013 no. (%)    12 (1.4)    19 (1.1)    0.83    (0.40-1.71)         Coronary heart death \u2013 no. (%)    5 (0.6)    8 (0.5)    0.80    (0.26-2.44)         First 4-point MACE \u2013 no. (%)    44 (5.2)    70 (4.2)    0.79    (0.54-1.15)         4-point MACE: C\u00a0HD \u00a0death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization . MACE was not a primary or secondary endpoint of the BROADWAY trial.         \u7e3d\u9ad4\u800c\u8a00\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u4ea6\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\uff08\u5305\u62ec\u8840\u58d3\uff09\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002Obicetrapib \u7d44\u4e2d\u6b62\u6cbb\u7642\u7387\u70ba 11.1%\uff0c\u5b89\u6170\u5291\u7684 12.4%\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d)\u3001\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\u4ee5\u53ca\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d) \u7684\u767c\u751f\u7387\u3002             Placebo (n=8\u00a043)    Obicetrapib 10 mg (n=1\u00a0,685)         Any TEAEs \u2013 no. (%)    513 (60.9)    1007 (59.8)         Any trial drug related TEAEs \u2013 no (%)    39 (4.6)    76 (4.5)         Any TEAEs leading to discontinuation of trial drug \u2013 no. (%    43 (5.1)    68 (4.0)         Any TESAEs \u2013 no. (%)    117 (13.9)    211 (12.5)         TANDEM \u8a66\u9a57\u7684\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u70ba\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5404\u55ae\u85e5\u6cbb\u7642\u7d44\u76f8\u6bd4\uff0c\u4ee5\u53ca Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\u3002\u6b21\u8981\u7d42\u9ede\u5305\u62ec\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7531\u57fa\u7dda\u8d77\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u5305\u62ec Lp(a)\u3001\u975e HDL-c \u548c APO B\u3002 TANDEM \u8a66\u9a57\u9054\u6210\u4e86\u6240\u6709\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u5176\u4e2d\u5305\u62ec\u5728\u7b2c 84 \u5929\u6642\uff0cObicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u9054\u5230 48.6% \u7684 LS \u5e73\u5747\u964d\u5e45 (p &lt; 0.0001)\u3002 \u7b2c 84 \u5929\u7684 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u00a0             Ezetimibe\u00a0 (n = 101)\u00a0    Obicetrapib (n = 102)\u00a0    Obicetrapib and Ezetimibe FDC\u00a0 (n = 102)\u00a0         Day 84 \u2013 from placebo                  Mean %    -23.3    -35.5    -52.2         Median %    -22.6    -37.2    -54.0         LS mean %    -20.7    -31.9    -48.6         Comparison to pbo    -    (p&lt;0.0001)    (p&lt;0.0001)         Comparison to eze 10 mg    -    -    (p&lt;0.0001)         Comparison to obi 10 mg    -    -    (p = 0.0007)         \u5728\u8a72\u8a66\u9a57\u4e2d\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d) \u53ca\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d)\u3002             Placebo (n=102)\u00a0    Ezetimibe (n=101)\u00a0    Obicetrapib (n=102)\u00a0    Obicetrapib \/ Ezetimibe FDC (n=102)\u00a0         Any study drug-related TEAEs    4 (3.9\u00a0%)    3 (3.0\u00a0%)    7 (6.9\u00a0%)    3 (2.9\u00a0%)         Any study drug-related TEAEs leading to discontinuation of study drug    2 (2.0\u00a0%)    1 (1.0\u00a0%)    6 (5.9\u00a0%)    1 (1.0\u00a0%)         Any study drug related TESAEs    0 (0.0\u00a0%)    0 (0.0\u00a0%)    0 (0.0\u00a0%)    0 (0.0\u00a0%)         \u300c\u5fc3\u8840\u7ba1\u75be\u75c5 (CVD) \u662f\u5168\u7403\u4e3b\u8981\u7684\u6b7b\u4ea1\u539f\u56e0\uff0c\u4f30\u8a08\u6bcf\u5e74\u596a\u53bb 1,790 \u842c\u4eba\u7684\u751f\u547d\u3002\u5118\u7ba1\u964d\u8102\u6cbb\u7642\u5df2\u5ee3\u6cdb\u61c9\u7528\uff0c\u4f46\u8207\u5fc3\u8840\u7ba1\u75be\u75c5\u76f8\u95dc\u7684\u6b7b\u4ea1\u4eba\u6578\u6709\u6240\u4e0a\u5347\uff0c\u4e14\u60a3\u8005\u7684 LDL-C \u6c34\u5e73\u4ecd\u7136\u8d85\u51fa\u76ee\u6a19\u503c\uff0c\u8a31\u591a\u60a3\u8005\u672a\u80fd\u9054\u5230\u6307\u5f15\u5efa\u8b70\u7684 LDL-C \u76ee\u6a19\u6c34\u5e73\u3002\u60a3\u8005\u53ca\u5176\u91ab\u751f\u9700\u8981\u5176\u4ed6\u6cbb\u7642\u9078\u64c7\u3002\u6211\u5011\u975e\u5e38\u9ad8\u8208 BROADWAY \u548c TANDEM \u7684\u6578\u64da\uff0c\u4ee5\u53ca\u5148\u524d\u516c\u4f48\u7684 BROOKLYN \u6578\u64da\uff0c\u5747\u8b49\u5be6\u4e86 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u80fd\u5920\u986f\u8457\u964d\u4f4e LDL-C\uff0c\u4e26\u5e6b\u52a9\u60a3\u8005\u9054\u5230\u5efa\u8b70\u7684\u76ee\u6a19\u6c34\u5e73\u3002\u9019\u4ee3\u8868\u8457\u6211\u5011\u81f4\u529b\u65bc\u70ba\u6b50\u6d32\u5fc3\u8840\u7ba1\u75be\u75c5\u60a3\u8005\u63d0\u4f9b\u6f5b\u5728\u540c\u985e\u9996\u5275\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u6cbb\u7642\u65b9\u6848\u7684\u91cd\u8981\u91cc\u7a0b\u7891\uff0c\u9019\u4ea6\u662f\u672c\u516c\u53f8\u4e09\u5341\u591a\u5e74\u4f86\u4e00\u76f4\u79c9\u6301\u7684\u4f7f\u547d\u300d\uff0cMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u70ba\u671f 52 \u9031\u7684\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u591a\u4e2d\u5fc3\u7814\u7a76\u8a55\u4f30\u4e86 10 mg Obicetrapib \u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u4f5c\u70ba\u6700\u5927\u8010\u53d7\u964d\u8102\u7642\u6cd5\u7684\u8f14\u52a9\u5291\uff0c\u5c08\u9580\u7528\u65bc LDL-C \u7121\u6cd5\u5145\u5206\u63a7\u5236\u7684 ASCVD \u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u8a72\u7814\u7a76\u5728\u5317\u7f8e\uff0c\u6b50\u6d32\uff0c\u4e9e\u6d32\u548c\u6fb3\u6d32\u7b49\u5730\u9032\u884c\u3002\u5171 2,530 \u540d\u60a3\u8005\u88ab\u96a8\u6a5f\u5206\u70ba\u5169\u7d44\uff0c\u6bd4\u4f8b\u70ba2:1\uff0c\u63a5\u53d7\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d 10 mg Obicetrapib \u6216\u5b89\u6170\u5291\u6cbb\u7642\uff0c\u70ba\u671f 52 \u9031\uff0c\u4e26\u4e14\u4e0d\u53d7\u98df\u7269\u5f71\u97ff\u3002\u5118\u7ba1\u8fd1 70% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 Obicetrapib \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 100 mg\/dL\u3002\u5973\u6027\u7d04\u4f54\u7814\u7a76\u5c0d\u8c61\u7684 34%\uff0c\u7814\u7a76\u53c3\u8207\u8005\u57fa\u6e96\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba 65 \u6b72\u3002 \u4e3b\u8981\u7d42\u9ede\u70ba Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u7d93\u586b\u88dc\u6cd5\u5206\u6790\u986f\u793a\u964d\u4f4e\u4e86 33%\u3002\u6b21\u8981\u7d42\u9ede\u4ea6\u5305\u62ec Obicetrapib 10 mg \u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929ApoB\u3001Lp(a)\u3001ApoA1\u3001HDL-C\u3001\u975eHDL-C\u3001\u7e3d\u81bd\u56fa\u9187\u53ca\u7518\u6cb9\u4e09\u916f\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u4ee5\u53ca\u7b2c 180 \u5929\u53ca\u7b2c 365 \u5929\u7684 LDL-C \u6c34\u5e73\uff08\u5206\u5225\u964d\u4f4e 34%\u53ca 24%\uff0cp&lt;0.0001\uff09\u3002\u5176\u4ed6\u7d50\u679c\u6307\u6a19\u5305\u62ec Obicetrapib \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u96a8\u6a5f\u5206\u7d44\u81f3\u9996\u6b21\u78ba\u8a3a\u767c\u751f MACE \u7684\u6642\u9593\u3002\u8a72\u8a66\u9a57\u9084\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u6a1e\u7d10\u6027\u7b2c\u4e09\u671f\u3001\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u56db\u7d44\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5c0d LDL-C \u6c34\u5e73\u7684\u5f71\u97ff\uff0c\u4e26\u8207 10 mg ezetimibe \u53ca 10 mg Obicetrapib 10 mg \u55ae\u85e5\u6cbb\u7642\u53ca\u5b89\u6170\u5291\u9032\u884c\u6bd4\u8f03\u3002\u8a72\u7814\u7a76\u65bc\u7f8e\u570b\u5404\u5730\u7684\u591a\u500b\u7814\u7a76\u4e2d\u5fc3\u9032\u884c\uff0c\u5171\u6709 407 \u540d\u57fa\u7dda LDL-C \u81f3\u5c11\u70ba70 mg\/dL\uff0c\u4e14\u60a3\u6709 HeFH \u53ca\/\u6216 ASCVD \u6216\u5177 ASCVD \u98a8\u96aa\u7b49\u540c\u60c5\u6cc1\u7684\u60a3\u8005\uff0c\u4ee5 1:1:1:1 \u7684\u6bd4\u4f8b\u96a8\u6a5f\u5206\u914d\u63a5\u53d7 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u300110 mg Obicetrapib\u300110 mg ezetimibe\u6216 \u5b89\u6170\u5291\uff0c\u6cbb\u7642\u671f\u70ba 84 \u5929\u3002\u5118\u7ba1\u7d04 74% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 obicetrapib-ezetimibe \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 97 mg\/dL\u3002\u9664\u8a55\u4f30\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u53ca\u6b21\u8981\u7d42\u9ede\u5916\uff0c\u8a72\u8a66\u9a57\u4ea6\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u3002 Obicetrapib\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u8a08\u5283 Obicetrapib \u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u5305\u62ec\u56db\u9805\u7814\u7a76\uff0c\u6d89\u53ca\u8d85\u904e 12,250 \u540d\u60a3\u8005\u3002\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u91dd\u5c0d Obicetrapib \u55ae\u7368\u6cbb\u7642\uff0c\u4e00\u9805\u5247\u8a55\u4f30 obicetrapib \u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u7d44\u5408 (\u300cFDC\u300d)\uff1a   BROOKLYN \u8a66\u9a57 (NCT05425745) \u5c0d\u65bc\u5728 HeFH \u4e0b\u4ecd\u672a\u80fd\u5145\u5206\u63a7\u5236 LDL-C \u7684\u60a3\u8005\uff0c\u8a55\u4f30\u5176\u4f7f\u7528 Obicetrapib \u7684\u6548\u679c\u30022023 \u5e74 4 \u6708\u5b8c\u6210\u8d85\u904e 350 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024\u5e74\u7b2c\u4e09\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002  BROADWAY \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u5c0d\u65bc\u60a3\u6709\u78ba\u5b9a\u7684 ASCVD \u53ca\/\u6216 HeFH \u7684\u6210\u5e74\u60a3\u8005\u7684\u6548\u679c\u3002\u5118\u7ba1\u9019\u4e9b\u60a3\u8005\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46\u5176 LDL-C \u6c34\u5e73\u4ecd\u672a\u80fd\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT05142722)\u30022023 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 2,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74\u7b2c\u56db\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002  TANDEM \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u4f5c\u70ba FDC \u7247\u5291\u7684\u4e00\u90e8\u5206\uff0c\u7528\u65bc\u60a3\u6709 ASCVD \u6216\u591a\u7a2e ASCVD \u98a8\u96aa\u56e0\u7d20\u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u9019\u4e9b\u60a3\u8005\u5118\u7ba1\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46 LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT06005597)\u3002 2024 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 400 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74 11 \u6708\u9304\u5f97\u9802\u7dda\u6578\u64da  PREVAIL \u662f\u4e00\u9805\u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57 (\u300cCVOT\u300d)\uff0c\u65e8\u5728\u8a55\u4f30\u6709 ASCVD \u75c5\u53f2\u7684\u60a3\u8005\uff0c\u5118\u7ba1\u5df2\u63a1\u7528\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0cObicetrapib \u5c0d\u65bc\u90a3\u4e9b LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u60a3\u8005\u7684\u6548\u679c (NCT05202509)\u30022024\u5e744\u6708\u5b8c\u6210\u8d85\u904e9500\u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u3002  \u95dc\u65bc Obicetrapib Obicetrapib \u662f\u4e00\u7a2e\u65b0\u578b\u7684\u53e3\u670d\u4f4e\u5291\u91cf CETP \u6291\u5236\u5291\uff0c\u65e8\u5728\u514b\u670d\u76ee\u524d\u964d\u4f4eLDL\u6cbb\u7642\u7684\u5c40\u9650\u6027\u3002\u5728\u5404\u9805\u7b2c\u4e8c\u671f\u8a66\u9a57 ROSE2\u3001TULIP\u3001ROSE\uff0c\u4ee5\u53ca\u7b2c\u4e09\u671f\u8a66\u9a57 BROOKLYN\u3001BROADWAY \u548c TANDEM \u4e2d\uff0c\u8a55\u4f30 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u806f\u5408\u6cbb\u7642\u6642\uff0c\u5747\u89c0\u5bdf\u5230\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684 LDL-C \u964d\u4f4e\uff0c\u4e14\u5176\u526f\u4f5c\u7528\u60c5\u6cc1\u8207\u5b89\u6170\u5291\u76f8\u4f3c\u3002\u7b2c\u4e09\u671f PREVAIL \u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57\u5728 2022 \u5e74 3 \u6708\u958b\u59cb\uff0c\u65e8\u5728\u8a55\u4f30 Obicetrapib \u6e1b\u5c11\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u7684\u6f5b\u529b\uff0c\u5305\u62ec\u5fc3\u8840\u7ba1\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u4e2d\u98a8\u548c\u975e\u9078\u64c7\u6027\u51a0\u72c0\u52d5\u8108\u518d\u8840\u7ba1\u5316\u30022024 \u5e74 4 \u6708 PREVAIL \u5b8c\u6210\u8d85\u904e 9,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\uff0c\u4e26\u9032\u884c\u96a8\u6a5f\u5206\u7d44\u3002 \u95dc\u65bc Menarini Group Menarini \u662f\u4e00\u5bb6\u9818\u5148\u570b\u969b\u88fd\u85e5\u548c\u8a3a\u65b7\u696d\u754c\u7684\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 47 \u5104\u7f8e\u5143\uff0c\u64c1\u6709\u8d85\u904e 17,000 \u540d\u54e1\u5de5\u3002Menarini\u5c08\u6ce8\u65bc\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80ba\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u3001\u708e\u75c7\u548c\u6b62\u75db\u7684\u7522\u54c1\uff0c\u5c08\u6ce8\u65bc\u9ad8\u672a\u6eff\u8db3\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u548c 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u92b7\u5f80\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc NewAmsterdam NewAmsterdam Pharma\uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS\uff09\u662f\u4e00\u9593\u5f8c\u671f\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5176\u4f7f\u547d\u662f\u5728\u73fe\u6709\u5df2\u7372\u6279\u51c6\u7684\u6cbb\u7642\u65b9\u6cd5\u4e0d\u8db3\u6216\u60a3\u8005\u8010\u53d7\u6027\u4e0d\u4f73\u7684\u60c5\u6cc1\u4e0b\uff0c\u6539\u5584\u4ee3\u8b1d\u75be\u75c5\u60a3\u8005\u7684\u8b77\u7406\u3002\u6211\u5011\u81f4\u529b\u65bc\u6eff\u8db3\u5c0d\u5b89\u5168\u3001\u8010\u53d7\u6027\u826f\u597d\u4e14\u4fbf\u6377\u7684\u4f4eLDL\u6cbb\u7642\u7684\u8feb\u5207\u9700\u6c42\u3002NewAmsterdam Pharmaceuticals \u6b63\u9032\u884c\u591a\u9805\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u53e3\u670d\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u7d66\u85e5\u7684 CETP \u6291\u5236\u5291 Obicetrapib \u55ae\u7368\u4f7f\u7528\uff0c\u6216\u8207 ezetimibe \u7d44\u6210\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u4f5c\u70ba\u964d\u4f4e LDL-C \u7684\u6548\u76ca\u3002\u6b64\u7b49\u7642\u6cd5\u64ec\u4f5c\u70ba\u5df2\u63a5\u53d7\u4ed6\u6c40\u985e\u85e5\u7269\u6cbb\u7642\uff0c\u60df LDL-C \u6fc3\u5ea6\u4ecd\u504f\u9ad8\uff0c\u4e14\u5177 CVD \u98a8\u96aa\uff0c\u73fe\u6709\u7642\u6cd5\u7642\u6548\u4e0d\u5f70\u6216\u8010\u53d7\u6027\u4e0d\u826f\u7684\u60a3\u8005\u7684\u8f14\u52a9\u6cbb\u7642\u65b9\u6848\u3002","og_url":"https:\/\/pingtungtimes.com.tw\/?p=284618","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2024-12-17T17:36:00+00:00","og_image":[{"width":400,"height":121,"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg","type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"2 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=284618#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=284618"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"Menarini Group \u516c\u4f48\u8a55\u4f30 Obicetrapib \u53ca\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291 Obicetrapib \u8207 Ezetimibe 10 mg \u7684\u95dc\u9375\u6027\u7b2c\u4e09\u671f BROADWAY \u53ca TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da","datePublished":"2024-12-17T17:36:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=284618"},"wordCount":422,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=284618#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=284618","url":"https:\/\/pingtungtimes.com.tw\/?p=284618","name":"Menarini Group \u516c\u4f48\u8a55\u4f30 Obicetrapib \u53ca\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291 Obicetrapib \u8207 Ezetimibe 10 mg \u7684\u95dc\u9375\u6027\u7b2c\u4e09\u671f BROADWAY \u53ca TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=284618#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=284618#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg","datePublished":"2024-12-17T17:36:00+00:00","description":"\u2014\u2014 \u5169\u9805\u95dc\u9375\u6027\u00a0\u7814\u7a76\u5747\u9054\u5230\u00a0\u4e3b\u8981\u7d42\u9ede\uff0c\u5728\u6700\u5927\u8010\u53d7\u5291\u91cf\u7684\u964d\u8102\u6cbb\u7642\u57fa\u790e\u4e0a\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (LDL-C) \u7684 LS \u5e73\u5747\u503c\u986f\u8457\u964d\u4f4e (p&lt;0.0001)\u3002 \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\uff08Obicetrapib \u55ae\u85e5\u6cbb\u7642\uff09 \u4e2d\uff0c\u7d04 50% \u7684\u00a0\u60a3\u8005 \u9054\u5230 LDL-C \u76ee\u6a19\u503c\u4f4e\u65bc 55 mg\/dL\uff1b \u800c \u00a0\u5728 TANDEM \u7814\u7a76\uff08Obicetrapib \u8207 Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff09\u4e2d\uff0c\u5247\u6709\u8d85\u904e 70% \u7684\u60a3\u8005\u9054\u5230\u76f8\u540c\u76ee\u6a19\u503c\u3002 \u2014\u2014 \u5728 BROADWAY \u7814\u7a76\u4e2d\uff0c\u4e00\u5e74\u6642\u89c0\u5bdf\u5230 Obicetrapib \u7684\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u00a0\u6e1b\u5c11 \u4e86 21%\uff0c\u986f\u793a\u51fa Obicetrapib \u7684\u512a\u52e2 \u2014\u2014 \u65bc\u5169\u9805\u7814\u7a76\u4e2d\uff0cObicetrapib \u55ae\u85e5\u7642\u6cd5\u53ca\u8207\u00a0Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5747\u986f\u793a\u51fa\u826f\u597d\u8010\u53d7\u6027 \u00a0 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u85a92024\u5e7412\u670817\u65e5 \/\u7f8e\u901a\u793e\/ -- Menarini Group\u4eca\u65e5\u516c\u4f48\u7531NewAmsterdam Pharma Company N.V. \uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS \u6216\u300cNewAmsterdam\u300d\u6216\u300c\u8a72\u516c\u53f8\u300d\uff09\u8d0a\u52a9\u7684\u7b2c\u4e09\u671fBROADWAY (NCT05142722) \u53caTANDEM (NCT06005597) \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da\u3002NewAmsterdam\u662f\u4e00\u5bb6\u5f8c\u671f\u81e8\u5e8a\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u70ba\u60a3\u6709\u9ad8\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\uff08\u300cLDL-C\u300d\uff09\u4e14\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\uff08\u300cCVD\u300d\uff09\u98a8\u96aa\uff0c\u800c\u73fe\u6709\u7642\u6cd5\u672a\u80fd\u5145\u5206\u6709\u6548\u6216\u826f\u597d\u8010\u53d7\u7684\u60a3\u8005\uff0c\u7814\u767c\u53e3\u670d\u975e\u4ed6\u6c40\u985e\u85e5\u7269\u3002 \u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57 (NCT05142722) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg\u00a0Obicetrapib \u5728\u60a3\u6709\u7570\u5408\u5b50\u5bb6\u65cf\u6027\u9ad8\u81bd\u56fa\u9187\u8840\u75c7 (\u300cHeFH\u300d) \u53ca\/\u6216\u5df2\u78ba\u8a3a\u52d5\u8108\u7ca5\u6a23\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u75be\u75c5 (\u300cASCVD\u300d)\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002 \u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57 (NCT06005597) \u7684\u8a2d\u8a08\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u548c 10 mg Ezetimibe \u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5728\u60a3\u6709 HeFH \u53ca\/\u6216\u5df2\u78ba\u8a3a ASCVD \u6216\u6709\u591a\u91cd ASCVD \u98a8\u96aa\u56e0\u7d20\uff0c\u5373\u4f7f\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u5291\u91cf\u964d\u8102\u6cbb\u7642\uff0c\u5176 LDL-C \u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u6210\u5e74\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u00a0 BROADWAY \u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u662f Obicetrapib 10 mg \u7d44\u76f8\u8f03\u65bc\u5b89\u6170\u5291\u7d44\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u7684\u6700\u5c0f\u4e8c\u4e58\u5e73\u5747\u503c\u3002\u4e3b\u8981\u7d42\u9ede\u9054\u5230\u7684\u7d71\u8a08\u610f\u7fa9\u6027\uff0cLDL-C \u964d\u4f4e 33% (p&lt;0.0001)\u3002 LDL-C percentage change at Day 84:\u00a0 Placebo\u00a0 (n=844)\u00a0 Obicetrapib 10 mg\u00a0 (n=1686)\u00a0 Difference Mean -2\u00a0% -35\u00a0% -33\u00a0% Median -4\u00a0% -40\u00a0% -36\u00a0% LS mean +3\u00a0% -30\u00a0% -33\u00a0% \u89c0\u5bdf\u5230\u7684\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7684\u8b8a\u5316\uff0c\u5305\u62ec\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (\u300cHDL-C\u300d) \u7684\u5347\u9ad8\u4ee5\u53ca\u975e\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187\u3001\u8102\u86cb\u767d (a)(\u300cLp(a)\u300d)\u3001\u8f09\u8102\u86cb\u767d B (\u300cApoB\u300d) \u548c\u8f09\u8102\u86cb\u767d A1 (ApoA1) \u7684\u964d\u4f4e\uff0c\u5747\u5448\u6b63\u9762\u8da8\u52e2\uff0c\u4e26\u8207\u5148\u524d\u81e8\u5e8a\u8a66\u9a57\u5831\u544a\u7684\u6578\u64da\u4e00\u81f4\u3002 \u4f5c\u70ba\u5b89\u5168\u6027\u5206\u6790\u7684\u4e00\u90e8\u5206\uff0c\u76e3\u6e2c\u4e86\u7279\u5225\u95dc\u6ce8\u7684\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6 (\u300cAE\u300d)\u3002\u5728\u9019\u4e9b AE \u4e2d\uff0c\u8840\u7cd6\u63a7\u5236\u548c\u814e\u529f\u80fd\u65b9\u9762\uff0cObicetrapib \u7d44\u5747\u512a\u65bc\u5c0d\u7167\u7d44\u3002 \u6b64\u5916\uff0cBROADWAY \u8a66\u9a57\u5c0d MACE \u9032\u884c\u4e86\u88c1\u5b9a\uff0c\u5305\u62ec\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u6027\u4e2d\u98a8\u548c\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u91cd\u5efa\u8853\uff0c\u7d50\u679c\u00a0\u986f\u793a Obicetrapib \u7d44\u7684\u9996\u500b\u56db\u9805 MACE \u4e8b\u4ef6\u767c\u751f\u7387\u964d\u4f4e\u4e86 21%\u3002 Major adverse cardiovascular events table:\u00a0 Placebo\u00a0 (n=844)\u00a0 Obicetrapib 10 mg\u00a0 (n= 1686)\u00a0 Hazard Ratio\u00a0 95% CI\u00a0 All-cause mortality \u2013 no. (%) 12 (1.4) 19 (1.1) 0.83 (0.40-1.71) Coronary heart death \u2013 no. (%) 5 (0.6) 8 (0.5) 0.80 (0.26-2.44) First 4-point MACE \u2013 no. (%) 44 (5.2) 70 (4.2) 0.79 (0.54-1.15) 4-point MACE: C\u00a0HD \u00a0death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization . MACE was not a primary or secondary endpoint of the BROADWAY trial. \u7e3d\u9ad4\u800c\u8a00\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u4ea6\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\uff08\u5305\u62ec\u8840\u58d3\uff09\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002Obicetrapib \u7d44\u4e2d\u6b62\u6cbb\u7642\u7387\u70ba 11.1%\uff0c\u5b89\u6170\u5291\u7684 12.4%\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d)\u3001\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\u4ee5\u53ca\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d) \u7684\u767c\u751f\u7387\u3002 Placebo (n=8\u00a043) Obicetrapib 10 mg (n=1\u00a0,685) Any TEAEs \u2013 no. (%) 513 (60.9) 1007 (59.8) Any trial drug related TEAEs \u2013 no (%) 39 (4.6) 76 (4.5) Any TEAEs leading to discontinuation of trial drug \u2013 no. (% 43 (5.1) 68 (4.0) Any TESAEs \u2013 no. (%) 117 (13.9) 211 (12.5) TANDEM \u8a66\u9a57\u7684\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u70ba\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5404\u55ae\u85e5\u6cbb\u7642\u7d44\u76f8\u6bd4\uff0c\u4ee5\u53ca Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\u3002\u6b21\u8981\u7d42\u9ede\u5305\u62ec\u5176\u4ed6\u751f\u7269\u6a19\u8a18\u7269\u7531\u57fa\u7dda\u8d77\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u5305\u62ec Lp(a)\u3001\u975e HDL-c \u548c APO B\u3002 TANDEM \u8a66\u9a57\u9054\u6210\u4e86\u6240\u6709\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u5176\u4e2d\u5305\u62ec\u5728\u7b2c 84 \u5929\u6642\uff0cObicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u9054\u5230 48.6% \u7684 LS \u5e73\u5747\u964d\u5e45 (p &lt; 0.0001)\u3002 \u7b2c 84 \u5929\u7684 LDL-C \u767e\u5206\u6bd4\u8b8a\u5316\u00a0 Ezetimibe\u00a0 (n = 101)\u00a0 Obicetrapib (n = 102)\u00a0 Obicetrapib and Ezetimibe FDC\u00a0 (n = 102)\u00a0 Day 84 \u2013 from placebo Mean % -23.3 -35.5 -52.2 Median % -22.6 -37.2 -54.0 LS mean % -20.7 -31.9 -48.6 Comparison to pbo - (p&lt;0.0001) (p&lt;0.0001) Comparison to eze 10 mg - - (p&lt;0.0001) Comparison to obi 10 mg - - (p = 0.0007) \u5728\u8a72\u8a66\u9a57\u4e2d\uff0c\u89c0\u5bdf\u5230 Obicetrapib \u8207 Ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5176\u5b89\u5168\u6027\u6578\u64da\u8207\u5b89\u6170\u5291\u7d44\u76f8\u82e5\u3002\u4e0b\u8868\u7e3d\u7d50\u4e86\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u4e0d\u826f\u4e8b\u4ef6 (\u300cTEAE\u300d) \u53ca\u8207\u7814\u7a76\u85e5\u7269\u76f8\u95dc\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6 (\u300cTESAE\u300d)\u3002 Placebo (n=102)\u00a0 Ezetimibe (n=101)\u00a0 Obicetrapib (n=102)\u00a0 Obicetrapib \/ Ezetimibe FDC (n=102)\u00a0 Any study drug-related TEAEs 4 (3.9\u00a0%) 3 (3.0\u00a0%) 7 (6.9\u00a0%) 3 (2.9\u00a0%) Any study drug-related TEAEs leading to discontinuation of study drug 2 (2.0\u00a0%) 1 (1.0\u00a0%) 6 (5.9\u00a0%) 1 (1.0\u00a0%) Any study drug related TESAEs 0 (0.0\u00a0%) 0 (0.0\u00a0%) 0 (0.0\u00a0%) 0 (0.0\u00a0%) \u300c\u5fc3\u8840\u7ba1\u75be\u75c5 (CVD) \u662f\u5168\u7403\u4e3b\u8981\u7684\u6b7b\u4ea1\u539f\u56e0\uff0c\u4f30\u8a08\u6bcf\u5e74\u596a\u53bb 1,790 \u842c\u4eba\u7684\u751f\u547d\u3002\u5118\u7ba1\u964d\u8102\u6cbb\u7642\u5df2\u5ee3\u6cdb\u61c9\u7528\uff0c\u4f46\u8207\u5fc3\u8840\u7ba1\u75be\u75c5\u76f8\u95dc\u7684\u6b7b\u4ea1\u4eba\u6578\u6709\u6240\u4e0a\u5347\uff0c\u4e14\u60a3\u8005\u7684 LDL-C \u6c34\u5e73\u4ecd\u7136\u8d85\u51fa\u76ee\u6a19\u503c\uff0c\u8a31\u591a\u60a3\u8005\u672a\u80fd\u9054\u5230\u6307\u5f15\u5efa\u8b70\u7684 LDL-C \u76ee\u6a19\u6c34\u5e73\u3002\u60a3\u8005\u53ca\u5176\u91ab\u751f\u9700\u8981\u5176\u4ed6\u6cbb\u7642\u9078\u64c7\u3002\u6211\u5011\u975e\u5e38\u9ad8\u8208 BROADWAY \u548c TANDEM \u7684\u6578\u64da\uff0c\u4ee5\u53ca\u5148\u524d\u516c\u4f48\u7684 BROOKLYN \u6578\u64da\uff0c\u5747\u8b49\u5be6\u4e86 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u80fd\u5920\u986f\u8457\u964d\u4f4e LDL-C\uff0c\u4e26\u5e6b\u52a9\u60a3\u8005\u9054\u5230\u5efa\u8b70\u7684\u76ee\u6a19\u6c34\u5e73\u3002\u9019\u4ee3\u8868\u8457\u6211\u5011\u81f4\u529b\u65bc\u70ba\u6b50\u6d32\u5fc3\u8840\u7ba1\u75be\u75c5\u60a3\u8005\u63d0\u4f9b\u6f5b\u5728\u540c\u985e\u9996\u5275\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u6cbb\u7642\u65b9\u6848\u7684\u91cd\u8981\u91cc\u7a0b\u7891\uff0c\u9019\u4ea6\u662f\u672c\u516c\u53f8\u4e09\u5341\u591a\u5e74\u4f86\u4e00\u76f4\u79c9\u6301\u7684\u4f7f\u547d\u300d\uff0cMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f BROADWAY \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u70ba\u671f 52 \u9031\u7684\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u591a\u4e2d\u5fc3\u7814\u7a76\u8a55\u4f30\u4e86 10 mg Obicetrapib \u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u4f5c\u70ba\u6700\u5927\u8010\u53d7\u964d\u8102\u7642\u6cd5\u7684\u8f14\u52a9\u5291\uff0c\u5c08\u9580\u7528\u65bc LDL-C \u7121\u6cd5\u5145\u5206\u63a7\u5236\u7684 ASCVD \u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u8a72\u7814\u7a76\u5728\u5317\u7f8e\uff0c\u6b50\u6d32\uff0c\u4e9e\u6d32\u548c\u6fb3\u6d32\u7b49\u5730\u9032\u884c\u3002\u5171 2,530 \u540d\u60a3\u8005\u88ab\u96a8\u6a5f\u5206\u70ba\u5169\u7d44\uff0c\u6bd4\u4f8b\u70ba2:1\uff0c\u63a5\u53d7\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d 10 mg Obicetrapib \u6216\u5b89\u6170\u5291\u6cbb\u7642\uff0c\u70ba\u671f 52 \u9031\uff0c\u4e26\u4e14\u4e0d\u53d7\u98df\u7269\u5f71\u97ff\u3002\u5118\u7ba1\u8fd1 70% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 Obicetrapib \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 100 mg\/dL\u3002\u5973\u6027\u7d04\u4f54\u7814\u7a76\u5c0d\u8c61\u7684 34%\uff0c\u7814\u7a76\u53c3\u8207\u8005\u57fa\u6e96\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba 65 \u6b72\u3002 \u4e3b\u8981\u7d42\u9ede\u70ba Obicetrapib 10 mg \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929 LDL-C \u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u7d93\u586b\u88dc\u6cd5\u5206\u6790\u986f\u793a\u964d\u4f4e\u4e86 33%\u3002\u6b21\u8981\u7d42\u9ede\u4ea6\u5305\u62ec Obicetrapib 10 mg \u8207\u5b89\u6170\u5291\u76f8\u6bd4\uff0c\u7531\u57fa\u7dda\u81f3\u7b2c 84 \u5929ApoB\u3001Lp(a)\u3001ApoA1\u3001HDL-C\u3001\u975eHDL-C\u3001\u7e3d\u81bd\u56fa\u9187\u53ca\u7518\u6cb9\u4e09\u916f\u7684\u767e\u5206\u6bd4\u8b8a\u5316\uff0c\u4ee5\u53ca\u7b2c 180 \u5929\u53ca\u7b2c 365 \u5929\u7684 LDL-C \u6c34\u5e73\uff08\u5206\u5225\u964d\u4f4e 34%\u53ca 24%\uff0cp&lt;0.0001\uff09\u3002\u5176\u4ed6\u7d50\u679c\u6307\u6a19\u5305\u62ec Obicetrapib \u7d44\u8207\u5b89\u6170\u5291\u7d44\u76f8\u6bd4\uff0c\u7531\u96a8\u6a5f\u5206\u7d44\u81f3\u9996\u6b21\u78ba\u8a3a\u767c\u751f MACE \u7684\u6642\u9593\u3002\u8a72\u8a66\u9a57\u9084\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\u3002 \u6a1e\u7d10\u6027\u7b2c\u4e09\u671f TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u8a2d\u8a08 \u9019\u9805\u6a1e\u7d10\u6027\u7b2c\u4e09\u671f\u3001\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u56db\u7d44\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u5c0d LDL-C \u6c34\u5e73\u7684\u5f71\u97ff\uff0c\u4e26\u8207 10 mg ezetimibe \u53ca 10 mg Obicetrapib 10 mg \u55ae\u85e5\u6cbb\u7642\u53ca\u5b89\u6170\u5291\u9032\u884c\u6bd4\u8f03\u3002\u8a72\u7814\u7a76\u65bc\u7f8e\u570b\u5404\u5730\u7684\u591a\u500b\u7814\u7a76\u4e2d\u5fc3\u9032\u884c\uff0c\u5171\u6709 407 \u540d\u57fa\u7dda LDL-C \u81f3\u5c11\u70ba70 mg\/dL\uff0c\u4e14\u60a3\u6709 HeFH \u53ca\/\u6216 ASCVD \u6216\u5177 ASCVD \u98a8\u96aa\u7b49\u540c\u60c5\u6cc1\u7684\u60a3\u8005\uff0c\u4ee5 1:1:1:1 \u7684\u6bd4\u4f8b\u96a8\u6a5f\u5206\u914d\u63a5\u53d7 10 mg Obicetrapib \u53ca 10 mg ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\u300110 mg Obicetrapib\u300110 mg ezetimibe\u6216 \u5b89\u6170\u5291\uff0c\u6cbb\u7642\u671f\u70ba 84 \u5929\u3002\u5118\u7ba1\u7d04 74% \u7684\u60a3\u8005\u5728\u7be9\u67e5\u671f\u9593\u5831\u544a\u4f7f\u7528\u4e86\u9ad8\u5f37\u5ea6\u7684\u4ed6\u6c40\u985e\u85e5\u7269\uff0c\u4f46\u5728 obicetrapib-ezetimibe \u7d44\u60a3\u8005\u7684\u5e73\u5747\u57fa\u6e96 LDL-C \u6c34\u5e73\u70ba 97 mg\/dL\u3002\u9664\u8a55\u4f30\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u53ca\u6b21\u8981\u7d42\u9ede\u5916\uff0c\u8a72\u8a66\u9a57\u4ea6\u8a55\u4f30\u4e86 Obicetrapib \u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u3002 Obicetrapib\u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u8a08\u5283 Obicetrapib \u5168\u7403\u95dc\u9375\u7b2c\u4e09\u671f\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u5305\u62ec\u56db\u9805\u7814\u7a76\uff0c\u6d89\u53ca\u8d85\u904e 12,250 \u540d\u60a3\u8005\u3002\u5176\u4e2d\u4e09\u9805\u7814\u7a76\u91dd\u5c0d Obicetrapib \u55ae\u7368\u6cbb\u7642\uff0c\u4e00\u9805\u5247\u8a55\u4f30 obicetrapib \u8207 ezetimibe \u7684\u56fa\u5b9a\u5291\u91cf\u7d44\u5408 (\u300cFDC\u300d)\uff1a BROOKLYN \u8a66\u9a57 (NCT05425745) \u5c0d\u65bc\u5728 HeFH \u4e0b\u4ecd\u672a\u80fd\u5145\u5206\u63a7\u5236 LDL-C \u7684\u60a3\u8005\uff0c\u8a55\u4f30\u5176\u4f7f\u7528 Obicetrapib \u7684\u6548\u679c\u30022023 \u5e74 4 \u6708\u5b8c\u6210\u8d85\u904e 350 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024\u5e74\u7b2c\u4e09\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002 BROADWAY \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u5c0d\u65bc\u60a3\u6709\u78ba\u5b9a\u7684 ASCVD \u53ca\/\u6216 HeFH \u7684\u6210\u5e74\u60a3\u8005\u7684\u6548\u679c\u3002\u5118\u7ba1\u9019\u4e9b\u60a3\u8005\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46\u5176 LDL-C \u6c34\u5e73\u4ecd\u672a\u80fd\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT05142722)\u30022023 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 2,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74\u7b2c\u56db\u5b63\u9304\u5f97\u9802\u7dda\u6578\u64da\u3002 TANDEM \u8a66\u9a57\u8a55\u4f30\u4e86 Obicetrapib \u4f5c\u70ba FDC \u7247\u5291\u7684\u4e00\u90e8\u5206\uff0c\u7528\u65bc\u60a3\u6709 ASCVD \u6216\u591a\u7a2e ASCVD \u98a8\u96aa\u56e0\u7d20\u53ca\/\u6216 HeFH \u60a3\u8005\u3002\u9019\u4e9b\u60a3\u8005\u5118\u7ba1\u5df2\u63a5\u53d7\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0c\u4f46 LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236 (NCT06005597)\u3002 2024 \u5e74 7 \u6708\u5b8c\u6210\u8d85\u904e 400 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u30022024 \u5e74 11 \u6708\u9304\u5f97\u9802\u7dda\u6578\u64da PREVAIL \u662f\u4e00\u9805\u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57 (\u300cCVOT\u300d)\uff0c\u65e8\u5728\u8a55\u4f30\u6709 ASCVD \u75c5\u53f2\u7684\u60a3\u8005\uff0c\u5118\u7ba1\u5df2\u63a1\u7528\u6700\u5927\u8010\u53d7\u7684\u964d\u8102\u7642\u6cd5\uff0cObicetrapib \u5c0d\u65bc\u90a3\u4e9b LDL-C \u6c34\u5e73\u4ecd\u672a\u5f97\u5230\u5145\u5206\u63a7\u5236\u7684\u60a3\u8005\u7684\u6548\u679c (NCT05202509)\u30022024\u5e744\u6708\u5b8c\u6210\u8d85\u904e9500\u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\u3002 \u95dc\u65bc Obicetrapib Obicetrapib \u662f\u4e00\u7a2e\u65b0\u578b\u7684\u53e3\u670d\u4f4e\u5291\u91cf CETP \u6291\u5236\u5291\uff0c\u65e8\u5728\u514b\u670d\u76ee\u524d\u964d\u4f4eLDL\u6cbb\u7642\u7684\u5c40\u9650\u6027\u3002\u5728\u5404\u9805\u7b2c\u4e8c\u671f\u8a66\u9a57 ROSE2\u3001TULIP\u3001ROSE\uff0c\u4ee5\u53ca\u7b2c\u4e09\u671f\u8a66\u9a57 BROOKLYN\u3001BROADWAY \u548c TANDEM \u4e2d\uff0c\u8a55\u4f30 Obicetrapib \u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u806f\u5408\u6cbb\u7642\u6642\uff0c\u5747\u89c0\u5bdf\u5230\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684 LDL-C \u964d\u4f4e\uff0c\u4e14\u5176\u526f\u4f5c\u7528\u60c5\u6cc1\u8207\u5b89\u6170\u5291\u76f8\u4f3c\u3002\u7b2c\u4e09\u671f PREVAIL \u5fc3\u8840\u7ba1\u7d50\u679c\u8a66\u9a57\u5728 2022 \u5e74 3 \u6708\u958b\u59cb\uff0c\u65e8\u5728\u8a55\u4f30 Obicetrapib \u6e1b\u5c11\u4e3b\u8981\u4e0d\u826f\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u7684\u6f5b\u529b\uff0c\u5305\u62ec\u5fc3\u8840\u7ba1\u6b7b\u4ea1\u3001\u975e\u81f4\u547d\u6027\u5fc3\u808c\u6897\u585e\u3001\u975e\u81f4\u547d\u4e2d\u98a8\u548c\u975e\u9078\u64c7\u6027\u51a0\u72c0\u52d5\u8108\u518d\u8840\u7ba1\u5316\u30022024 \u5e74 4 \u6708 PREVAIL \u5b8c\u6210\u8d85\u904e 9,500 \u540d\u60a3\u8005\u7684\u7814\u7a76\u5831\u540d\uff0c\u4e26\u9032\u884c\u96a8\u6a5f\u5206\u7d44\u3002 \u95dc\u65bc Menarini Group Menarini \u662f\u4e00\u5bb6\u9818\u5148\u570b\u969b\u88fd\u85e5\u548c\u8a3a\u65b7\u696d\u754c\u7684\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 47 \u5104\u7f8e\u5143\uff0c\u64c1\u6709\u8d85\u904e 17,000 \u540d\u54e1\u5de5\u3002Menarini\u5c08\u6ce8\u65bc\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80ba\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u3001\u708e\u75c7\u548c\u6b62\u75db\u7684\u7522\u54c1\uff0c\u5c08\u6ce8\u65bc\u9ad8\u672a\u6eff\u8db3\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u548c 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u92b7\u5f80\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc NewAmsterdam NewAmsterdam Pharma\uff08\u7d0d\u65af\u9054\u514b\u80a1\u7968\u4ee3\u78bc\uff1aNAMS\uff09\u662f\u4e00\u9593\u5f8c\u671f\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5176\u4f7f\u547d\u662f\u5728\u73fe\u6709\u5df2\u7372\u6279\u51c6\u7684\u6cbb\u7642\u65b9\u6cd5\u4e0d\u8db3\u6216\u60a3\u8005\u8010\u53d7\u6027\u4e0d\u4f73\u7684\u60c5\u6cc1\u4e0b\uff0c\u6539\u5584\u4ee3\u8b1d\u75be\u75c5\u60a3\u8005\u7684\u8b77\u7406\u3002\u6211\u5011\u81f4\u529b\u65bc\u6eff\u8db3\u5c0d\u5b89\u5168\u3001\u8010\u53d7\u6027\u826f\u597d\u4e14\u4fbf\u6377\u7684\u4f4eLDL\u6cbb\u7642\u7684\u8feb\u5207\u9700\u6c42\u3002NewAmsterdam Pharmaceuticals \u6b63\u9032\u884c\u591a\u9805\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u53e3\u670d\u3001\u4f4e\u5291\u91cf\u3001\u6bcf\u65e5\u4e00\u6b21\u7d66\u85e5\u7684 CETP \u6291\u5236\u5291 Obicetrapib \u55ae\u7368\u4f7f\u7528\uff0c\u6216\u8207 ezetimibe \u7d44\u6210\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291\uff0c\u4f5c\u70ba\u964d\u4f4e LDL-C \u7684\u6548\u76ca\u3002\u6b64\u7b49\u7642\u6cd5\u64ec\u4f5c\u70ba\u5df2\u63a5\u53d7\u4ed6\u6c40\u985e\u85e5\u7269\u6cbb\u7642\uff0c\u60df LDL-C \u6fc3\u5ea6\u4ecd\u504f\u9ad8\uff0c\u4e14\u5177 CVD \u98a8\u96aa\uff0c\u73fe\u6709\u7642\u6cd5\u7642\u6548\u4e0d\u5f70\u6216\u8010\u53d7\u6027\u4e0d\u826f\u7684\u60a3\u8005\u7684\u8f14\u52a9\u6cbb\u7642\u65b9\u6848\u3002","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=284618#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=284618"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=284618#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg","width":400,"height":121},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=284618#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"Menarini Group \u516c\u4f48\u8a55\u4f30 Obicetrapib \u53ca\u56fa\u5b9a\u5291\u91cf\u8907\u65b9\u88fd\u5291 Obicetrapib \u8207 Ezetimibe 10 mg \u7684\u95dc\u9375\u6027\u7b2c\u4e09\u671f BROADWAY \u53ca TANDEM \u81e8\u5e8a\u8a66\u9a57\u7684\u6b63\u9762\u9802\u7dda\u6578\u64da"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/284618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=284618"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/284618\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/284619"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=284618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=284618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=284618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}